Supplementary Table 7 _713K_ - Nature.com

Document Sample
Supplementary Table 7 _713K_ - Nature.com Powered By Docstoc
					Coordinates               Genotype
Gene, amino acid change   Trait-associated allele
chr1:65809029             A/G
LEPR, K109R               G
chr1:65831101             G/G
LEPR, Q223R               G
chr1:98121473             G/A
DPYD, C29R                G
chr1:167963570            G/A
SELE, H468Y               A
chr1:194908856            G/A
CFH, I62V                 G
chr1:201460809            C/T
CHIT1, G102S              T
chr1:224093029            A/G
EPHX1, H139R              G
chr2:108880033            G/G
EDAR, V370A               G
chr2:230758959            G/G
SP110, L425S              G
chr2:233848107            A/G
ATG16L1, T300A            G
chr2:234333883            G/A
UGT1A1, G71R              A
chr2:234333883            G/A
UGT1A1, G71R              A
chr3:10306457             G/T
GHRL, L72M                T
chr3:10306457             G/T
GHRL, L72M                T
chr4:2876505              T/T
ADD1, G460W               T
chr5:74020971             A/G
HEXB, K121R               G
chr5:148186633            G/A
ADRB2, R16G               G
chr5:148186633            G/A
ADRB2, R16G               G
chr5:176452849            G/A
FGFR4, G388R              A
chr6:16398740             A/A
GMPR, F256I               A
chr7:34784638             T/T
NPSR1, N107I              T
chr7:94775382             C/C
PON1, Q192R               C
chr7:94775382             C/C
PON1, Q192R               C
chr7:94775382             C/C
PON1, Q192R               C
chr7:141319073            T/C
TAS2R38, I296V            C
chr7:141319174            G/A
TAS2R38, V262A            G
chr7:141319814            C/G
TAS2R38, A49P             G
chr8:18302383             G/A
NAT2, R197Q               A
chr8:27429782             G/A
EPHX2, R287Q      A
chr8:118253964    C/T
SLC30A8, R325W    T
chr8:133969434    G/G
TG, S734A         G
chr9:106660688    C/T
ABCA1, R219K      T
chr10:13218772    G/A
OPTN, R545Q       A
chr10:54201241    C/T
MBL2, G54D        T
chr10:54201241    C/T
MBL2, G54D        T
chr10:70311866    T/C
STOX1, Y153H      C
chr10:70315382    A/C
STOX1, E608D      C
chr10:75343107    T/C
PLAU, P141L       T
chr11:59619680    A/G
MS4A2, E237G      G
chr11:66084671    T/C
ACTN3, R577*      T
chr11:66084671    T/C
ACTN3, R577*      T
chr11:66084671    T/C
ACTN3, R577*      T
chr11:68611939    A/A
TPCN2, G734E      A
chr11:73394991    G/A
UCP3, R70W        A
chr11:116166602   C/A
APOA5, G185C      A
chr12:111833253   G/A
OAS1, S162G       G
chr14:60993992    G/A
PRKCH, V374I      A
chr14:63978598    G/A
MTHFD1, R653Q     A
chr14:63978598    G/A
MTHFD1, R653Q     A
chr15:72006599    T/T
LOXL1, R141L      T
chr16:3239469     C/T
MEFV, R408Q       T
chr16:3239587     G/A
MEFV, P369S       A
chr16:3244627     C/G
MEFV, E148Q       G
chr16:3647748     G/A
DNASE1, Q244R     G
chr16:16159100    C/T
ABCC6, R1268Q     T
chr16:46815699    T/T
ABCC11, G180R     T
chr17:7847244     T/T
GUCY2D, A52S      T
chr17:19753133    T/C
AKAP10, I646V     C
chr17:25600202    C/C
BLMH, I443V       C
chr17:39694471   T/C
SLC4A1, K56E     C
chr17:59804699   C/C
PECAM1, L125V    C
chr17:75701636   G/A
GAA, E689K       A
chr18:9107867    T/C
NDUFV2, A29V     T
chr19:50014584   A/G
BCAM, T539A      G
chr20:3141842    C/A
ITPA, P32T       A
chr20:54394948   A/T
AURKA, F31I      T
chr21:33562658   A/G
IL10RB, E47K     A
chr22:18331271   G/A
COMT, V158M      A
chr22:40856638   G/A
CYP2D6, P34S     A
                         Associated trait


                LEPTIN RECEPTOR POLYMORPHISM

                LEPTIN RECEPTOR POLYMORPHISM

         DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY

              IgA NEPHROPATHY, SUSCEPTIBILITY TO

   MACULAR DEGENERATION, AGE-RELATED, 4, SUSCEPTIBILITY TO

                  CHITOTRIOSIDASE DEFICIENCY

               EPOXIDE HYDROLASE POLYMORPHISM

              HAIR MORPHOLOGY 1, HAIR THICKNESS

        MYCOBACTERIUM TUBERCULOSIS, SUSCEPTIBILITY TO

       INFLAMMATORY BOWEL DISEASE 10, SUSCEPTIBILITY TO

                      GILBERT SYNDROME

   HYPERBILIRUBINEMIA, TRANSIENT FAMILIAL NEONATAL, INCLUDED

       METABOLIC SYNDROME, SUSCEPTIBILITY TO, INCLUDED

                   OBESITY, AGE AT ONSET OF

   HYPERTENSION, SALT-SENSITIVE ESSENTIAL, SUSCEPTIBILITY TO

                      HEXB POLYMORPHISM

             ASTHMA, NOCTURNAL, SUSCEPTIBILITY TO

       METABOLIC SYNDROME, SUSCEPTIBILITY TO, INCLUDED

         CANCER PROGRESSION AND TUMOR CELL MOTILITY

                GMP REDUCTASE POLYMORPHISM

                    ASTHMA SUSCEPTIBILITY 2

     CORONARY ARTERY DISEASE, SUSCEPTIBILITY TO, INCLUDED

     CORONARY ARTERY SPASM, SUSCEPTIBILITY TO, INCLUDED

               PON1 ENZYME ACTIVITY, VARIATION IN

                PHENYLTHIOCARBAMIDE TASTING

                PHENYLTHIOCARBAMIDE TASTING

                PHENYLTHIOCARBAMIDE TASTING

                      ACETYLATION, SLOW

HYPERCHOLESTEROLEMIA, FAMILIAL, DUE TO LDLR DEFECT, MODIFIER OF
HYPERCHOLESTEROLEMIA, FAMILIAL, DUE TO LDLR DEFECT, MODIFIER OF

  DIABETES MELLITUS, NONINSULIN-DEPENDENT, SUSCEPTIBILITY TO

       AUTOIMMUNE THYROID DISEASE, SUSCEPTIBILITY TO, 3

  CORONARY HEART DISEASE IN FAMILIAL HYPERCHOLESTEROLEMIA,
                    PROTECTION AGAINST

                   GLAUCOMA 1, OPEN ANGLE, E

  GESTATIONAL DIABETES MELLITUS, SUSCEPTIBILITY TO, INCLUDED

             MANNOSE-BINDING PROTEIN DEFICIENCY

                   PREECLAMPSIA/ECLAMPSIA 4

                   PREECLAMPSIA/ECLAMPSIA 4

        ALZHEIMER DISEASE, LATE-ONSET, SUSCEPTIBILITY TO

               ATOPIC ASTHMA, SUSCEPTIBILITY TO

                 ACTININ, ALPHA-3 POLYMORPHISM

                       ACTN3 DEFICIENCY

                    SPRINTING PERFORMANCE

        SKIN/HAIR/EYE PIGMENTATION 10, BLOND/BROWN HAIR

              OBESITY, SEVERE, AND TYPE II DIABETES

            HYPERTRIGLYCERIDEMIA, SUSCEPTIBILITY TO

          DIABETES MELLITUS, TYPE 1, SUSCEPTIBILITY TO

            CEREBRAL INFARCTION, SUSCEPTIBILITY TO

        ABRUPTIO PLACENTAE, SUSCEPTIBILITY TO, INCLUDED

   NEURAL TUBE DEFECTS, FOLATE-SENSITIVE, SUSCEPTIBILITY TO

           EXFOLIATION SYNDROME, SUSCEPTIBILITY TO

                 FAMILIAL MEDITERRANEAN FEVER

                 FAMILIAL MEDITERRANEAN FEVER

                 FAMILIAL MEDITERRANEAN FEVER

       SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO

                  PSEUDOXANTHOMA ELASTICUM

                       EAR WAX, WET/DRY

              LEBER CONGENITAL AMAUROSIS, TYPE I

         CARDIAC CONDUCTION DEFECT, SUSCEPTIBILITY TO

             BLEOMYCIN HYDROLASE POLYMORPHISM
                      BAND 3 MEMPHIS

PLATELET-ENDOTHELIAL CELL ADHESION MOLECULE 1 POLYMORPHISM

             ACID ALPHA-GLUCOSIDASE, ALLELE 4

            PARKINSON DISEASE, SUSCEPTIBILITY TO

      AUBERGER BLOOD GROUP POLYMORPHISM Au(a)/Au(b)

            INOSINE TRIPHOSPHATASE DEFICIENCY

              COLON CANCER, SUSCEPTIBILITY TO

            HEPATITIS B VIRUS, SUSCEPTIBILITY TO

       CATECHOL-O-METHYLTRANSFERASE POLYMORPHISM

            DEBRISOQUINE, POOR METABOLISM OF
Coordinates               Genotype
Gene, amino acid change   Trait-associated allele
chr1:9246497              G/A
H6PD, R453Q               A
chr1:25589952             C/G
RHCE, P226A               C
chr1:46643348             C/A
FAAH, P129T               A
chr1:65809029             G/G
LEPR, K109R               G
chr1:65831101             G/G
LEPR, Q223R               G
chr1:167963570            G/A
SELE, H468Y               A
chr1:194925860            C/T
CFH, Y402H                C
chr1:194925860            C/T
CFH, Y402H                C
chr1:205173101            A/A
PIGR, A580V               A
chr1:224086256            T/C
EPHX1, Y113H              C
chr1:224086256            T/C
EPHX1, Y113H              C
chr1:224086256            T/C
EPHX1, Y113H              C
chr1:224086256            T/C
EPHX1, Y113H              C
chr2:108880033            G/G
EDAR, V370A               G
chr2:230758959            G/G
SP110, L425S              G
chr3:46374212             G/A
CCR2, V64I                A
chr4:2876505              T/T
ADD1, G460W               T
chr4:100458342            T/C
ADH1B, R48H               T
chr4:100458342            T/C
ADH1B, R48H               T
chr4:100479812            T/C
ADH1C, I350V              C
chr4:100482988            C/T
ADH1C, R272Q              T
chr4:102970099            G/A
BANK1, R61H               A
chr5:7923973              A/G
MTRR, I22M                G
chr5:7923973              A/G
MTRR, I22M                G
chr5:35896825             T/C
IL7R, T66I                T
chr5:35896825             T/C
IL7R, T66I                T
chr6:12404241             G/T
EDN1, K198N               T
chr6:12404241     G/T
EDN1, K198N       T
chr6:16398740     T/A
GMPR, F256I       A
chr6:32904729     T/C
TAP2, A665T       T
chr7:34784638     A/T
NPSR1, N107I      T
chr7:94784020     A/T
PON1, L55M        T
chr7:94784020     A/T
PON1, L55M        T
chr7:94784020     A/T
PON1, L55M        T
chr7:94872711     G/C
PON2, C311S       G
chr7:94878952     G/C
PON2, A148G       C
chr7:116986769    G/A
CFTR, M470V       G
chr7:141319073    T/C
TAS2R38, I296V    C
chr7:141319174    G/A
TAS2R38, V262A    G
chr7:141319814    C/G
TAS2R38, A49P     G
chr8:18302134     T/C
NAT2, I114T       C
chr8:18302596     G/A
NAT2, K268R       G
chr8:118253964    C/T
SLC30A8, R325W    T
chr8:133969434    T/G
TG, S734A         G
chr9:106660688    C/T
ABCA1, R219K      T
chr10:70311866    C/C
STOX1, Y153H      C
chr11:27636492    C/T
BDNF, V66M        T
chr11:27636492    C/T
BDNF, V66M        T
chr11:27636492    C/T
BDNF, V66M        T
chr11:27636492    C/T
BDNF, V66M        T
chr11:27636492    C/T
BDNF, V66M        T
chr11:27636492    C/T
BDNF, V66M        T
chr11:48101951    A/C
PTPRJ, Q276P      C
chr12:9123535     T/C
A2M, V1000I       T
chr12:9123535     T/C
A2M, V1000I       T
chr12:110726149   G/A
ALDH2, E504K      A
chr12:110726149   G/A
ALDH2, E504K      A
chr12:110726149   G/A
ALDH2, E504K      A
chr12:120779718   T/C
HPD, A33T         T
chr13:31804729    A/C
BRCA2, N372H      C
chr14:60993992    G/A
PRKCH, V374I      A
chr16:16159100    C/T
ABCC6, R1268Q     T
chr16:46815699    T/T
ABCC11, G180R     T
chr16:68302646    A/A
NQO1, P187S       A
chr16:68302646    A/A
NQO1, P187S       A
chr16:68302646    A/A
NQO1, P187S       A
chr16:88513441    G/A
MC1R, V92M        A
chr16:88513441    G/A
MC1R, V92M        A
chr17:5426091     A/T
NLRP1, L155H      T
chr17:39694471    T/C
SLC4A1, K56E      C
chr17:59804699    G/C
PECAM1, L125V     C
chr20:54394948    T/T
AURKA, F31I       T
chrX:19285703     A/C
PDHA1, M282L      C
                        Associated trait

              CORTISONE REDUCTASE DEFICIENCY

                    RH E/e POLYMORPHISM

              DRUG ADDICTION, SUSCEPTIBILITY TO

               LEPTIN RECEPTOR POLYMORPHISM

               LEPTIN RECEPTOR POLYMORPHISM

             IgA NEPHROPATHY, SUSCEPTIBILITY TO

               BASAL LAMINAR DRUSEN, INCLUDED

   MACULAR DEGENERATION, AGE-RELATED, 4, SUSCEPTIBILITY TO

             IgA NEPHROPATHY, SUSCEPTIBILITY TO

           EMPHYSEMA, SUSCEPTIBILITY TO, INCLUDED

      LYMPHOPROLIFERATIVE DISORDERS, SUSCEPTIBILITY TO

          PREECLAMPSIA, SUSCEPTIBILITY TO, INCLUDED

 PULMONARY DISEASE, CHRONIC OBSTRUCTIVE, SUSCEPTIBILITY TO,
                        INCLUDED

             HAIR MORPHOLOGY 1, HAIR THICKNESS

       MYCOBACTERIUM TUBERCULOSIS, SUSCEPTIBILITY TO

     HUMAN IMMUNODEFICIENCY VIRUS TYPE 1, RESISTANCE TO

  HYPERTENSION, SALT-SENSITIVE ESSENTIAL, SUSCEPTIBILITY TO

AERODIGESTIVE TRACT CANCER, SQUAMOUS CELL, ALCOHOL-RELATED,
                PROTECTION AGAINST; INCLUDED

          ALCOHOL DEPENDENCE, PROTECTION AGAINST

          ALCOHOL DEPENDENCE, PROTECTION AGAINST

          ALCOHOL DEPENDENCE, PROTECTION AGAINST

       SYSTEMIC LUPUS ERYTHMATOSUS, ASSOCIATION WITH

         DOWN SYNDROME, SUSCEPTIBILITY TO, INCLUDED

   NEURAL TUBE DEFECTS, FOLATE-SENSITIVE, SUSCEPTIBILITY TO

               B CELL-POSITIVE, NK CELL-POSITIVE

 SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T
                      CELL-NEGATIVE,

                               7
HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT
                            LOCUS

                GMP REDUCTASE POLYMORPHISM

          PEPTIDE TRANSPORTER PSF2 POLYMORPHISM

                   ASTHMA SUSCEPTIBILITY 2

    CORONARY ARTERY DISEASE, SUSCEPTIBILITY TO, INCLUDED

MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 5,
                        INCLUDED

              PON1 ENZYME ACTIVITY, VARIATION IN

                PARAOXONASE 2 POLYMORPHISM

                PARAOXONASE 2 POLYMORPHISM

                     CFTR POLYMORPHISM

                PHENYLTHIOCARBAMIDE TASTING

                PHENYLTHIOCARBAMIDE TASTING

                PHENYLTHIOCARBAMIDE TASTING

                      ACETYLATION, SLOW

                      ACETYLATION, SLOW

 DIABETES MELLITUS, NONINSULIN-DEPENDENT, SUSCEPTIBILITY TO

       AUTOIMMUNE THYROID DISEASE, SUSCEPTIBILITY TO, 3

 CORONARY HEART DISEASE IN FAMILIAL HYPERCHOLESTEROLEMIA,
                   PROTECTION AGAINST

                  PREECLAMPSIA/ECLAMPSIA 4

       ANOREXIA NERVOSA, SUSCEPTIBILITY TO, 2, INCLUDED

   BIPOLAR AFFECTIVE DISORDER, SUSCEPTIBILITY TO, INCLUDED

        BULIMIA NERVOSA, SUSCEPTIBILITY TO, 2, INCLUDED

            MEMORY IMPAIRMENT, SUSCEPTIBILITY TO

OBSESSIVE-COMPULSIVE DISORDER, PROTECTION AGAINST, INCLUDED

 PARKINSON DISEASE, AGE AT ONSET, SUSCEPTIBILITY TO, INCLUDED

                   COLON CANCER, SOMATIC

            ALPHA-2-MACROGLOBULIN POLYMORPHISM

        ALZHEIMER DISEASE, SUSCEPTIBILITY TO, INCLUDED

                 ALCOHOL SENSITIVITY, ACUTE
                  ALCOHOL SENSITIVITY, ACUTE

            HANGOVER, SUSCEPTIBILITY TO, INCLUDED

SUBLINGUAL NITROGLYCERIN, SUSCEPTIBILITY TO POOR RESPONSE TO,
                          INCLUDED

                        HAWKINSINURIA

     BREAST-OVARIAN CANCER, FAMILIAL, SUSCEPTIBILITY TO, 2

            CEREBRAL INFARCTION, SUSCEPTIBILITY TO

                 PSEUDOXANTHOMA ELASTICUM

                       EAR WAX, WET/DRY

              BENZENE TOXICITY, SUSCEPTIBILITY TO

BREAST CANCER, POST-CHEMOTHERAPY POOR SURVIVAL IN, INCLUDED

  LEUKEMIA, POST-CHEMOTHERAPY, SUSCEPTIBILITY TO, INCLUDED

  SKIN/HAIR/EYE PIGMENTATION 2, BLOND HAIR/FAIR SKIN, INCLUDED

        SKIN/HAIR/EYE PIGMENTATION 2, RED HAIR/FAIR SKIN

VITILIGO-ASSOCIATED MULTIPLE AUTOIMMUNE DISEASE SUSCEPTIBILITY
                               1

                        BAND 3 MEMPHIS

PLATELET-ENDOTHELIAL CELL ADHESION MOLECULE 1 POLYMORPHISM

               COLON CANCER, SUSCEPTIBILITY TO

        PYRUVATE DEHYDROGENASE E1-ALPHA DEFICIENCY
Coordinates               Genotype
Gene, amino acid change   Trait-associated allele
chr1:25589952             C/G
RHCE, P226A               C
chr1:46643348             C/A
FAAH, P129T               A
chr1:65809029             G/G
LEPR, K109R               G
chr1:65831101             G/G
LEPR, Q223R               G
chr1:152693594            C/C
IL6R, D358A               C
chr1:167963570            G/A
SELE, H468Y               A
chr1:169346704            A/A
FMO3, V257M               A
chr1:221351222            T/C
TLR5, N592S               C
chr1:221351823            G/A
TLR5, R392*               A
chr1:221351823            G/A
TLR5, R392*               A
chr2:49043425             C/T
FSHR, N680S               C
chr2:49043425             C/T
FSHR, N680S               C
chr2:49044545             C/T
FSHR, T307A               C
chr2:108880033            G/G
EDAR, V370A               G
chr2:230758959            G/G
SP110, L425S              G
chr2:233848107            A/G
ATG16L1, T300A            G
chr3:46374212             G/A
CCR2, V64I                A
chr3:46390065             G/A
CCR5, R223Q               A
chr4:2876505              G/T
ADD1, G460W               T
chr5:33999627             C/T
SLC45A2, E272K            T
chr5:33999627             C/T
SLC45A2, E272K            T
chr5:33999627             C/T
SLC45A2, E272K            T
chr5:35896825             T/C
IL7R, T66I                T
chr5:35896825             T/C
IL7R, T66I                T
chr5:35906947             G/A
IL7R, I138V               G
chr5:35906947             G/A
IL7R, I138V               G
chr5:147461148            A/G
SPINK5, E420K             A
chr5:147461148   A/G
SPINK5, E420K    A
chr5:147461148   A/G
SPINK5, E420K    A
chr6:12404241    T/T
EDN1, K198N      T
chr6:12404241    T/T
EDN1, K198N      T
chr6:16398740    T/A
GMPR, F256I      A
chr6:32908390    C/T
TAP2, I379V      C
chr6:149763383   G/A
SUMO4, M55V      G
chr7:94775382    C/C
PON1, Q192R      C
chr7:94775382    C/C
PON1, Q192R      C
chr7:94775382    C/C
PON1, Q192R      C
chr7:141319073   T/C
TAS2R38, I296V   C
chr7:141319174   G/A
TAS2R38, V262A   G
chr8:18302596    G/A
NAT2, K268R      G
chr8:27429782    G/A
EPHX2, R287Q     A
chr8:118253964   C/T
SLC30A8, R325W   T
chr9:106660688   C/T
ABCA1, R219K     T
chr9:115193712   C/G
ALAD, K59N       G
chr10:70311866   T/C
STOX1, Y153H     C
chr10:70315382   A/C
STOX1, E608D     C
chr11:27636492   T/T
BDNF, V66M       T
chr11:27636492   T/T
BDNF, V66M       T
chr11:27636492   T/T
BDNF, V66M       T
chr11:27636492   T/T
BDNF, V66M       T
chr11:27636492   T/T
BDNF, V66M       T
chr11:27636492   T/T
BDNF, V66M       T
chr11:48101951   A/C
PTPRJ, Q276P     C
chr11:59619680   A/G
MS4A2, E237G     G
chr11:66084671   T/C
ACTN3, R577*     T
chr11:66084671   T/C
ACTN3, R577*      T
chr11:66084671    T/C
ACTN3, R577*      T
chr11:68611939    G/A
TPCN2, G734E      A
chr12:9123535     T/C
A2M, V1000I       T
chr12:9123535     T/C
A2M, V1000I       T
chr12:111833253   G/A
OAS1, S162G       G
chr13:107661592   G/A
LIG4, T9I         A
chr13:107661610   G/A
LIG4, A3V         A
chr14:60993992    G/A
PRKCH, V374I      A
chr15:48665922    G/A
TRPM7, T1482I     A
chr15:63281265    G/G
CILP, I395T       G
chr16:3239469     C/T
MEFV, R408Q       T
chr16:27281681    T/C
IL4R, S503P       C
chr16:27281681    T/C
IL4R, S503P       C
chr16:46815699    T/T
ABCC11, G180R     T
chr16:68302646    G/A
NQO1, P187S       A
chr16:68302646    G/A
NQO1, P187S       A
chr16:68302646    G/A
NQO1, P187S       A
chr17:59804699    G/C
PECAM1, L125V     C
chr18:9107867     T/C
NDUFV2, A29V      T
chr21:33536120    T/C
IFNAR2, S8F       T
chr21:33562658    A/G
IL10RB, E47K      A
chr22:40856638    A/A
CYP2D6, P34S      A
chrX:19285703     C
PDHA1, M282L      C
                         Associated trait

                      RH E/e POLYMORPHISM

               DRUG ADDICTION, SUSCEPTIBILITY TO

                LEPTIN RECEPTOR POLYMORPHISM

                LEPTIN RECEPTOR POLYMORPHISM

        INTERLEUKIN-6 SOLUBLE RECEPTOR, SERUM LEVEL OF

               IgA NEPHROPATHY, SUSCEPTIBILITY TO

                       TRIMETHYLAMINURIA

             LEGIONNAIRE DISEASE, SUSCEPTIBILITY TO

             LEGIONNAIRE DISEASE, SUSCEPTIBILITY TO

   SYSTEMIC LUPUS ERYTHEMATOSUS, RESISTANCE TO, 1, INCLUDED

 OVARIAN HYPERSTIMULATION SYNDROME, MODIFIER OF SEVERITY OF,
                         INCLUDED

             OVARIAN RESPONSE TO FSH STIMULATION

             OVARIAN RESPONSE TO FSH STIMULATION

               HAIR MORPHOLOGY 1, HAIR THICKNESS

        MYCOBACTERIUM TUBERCULOSIS, SUSCEPTIBILITY TO

       INFLAMMATORY BOWEL DISEASE 10, SUSCEPTIBILITY TO

      HUMAN IMMUNODEFICIENCY VIRUS TYPE 1, RESISTANCE TO

                 CCR5 POLYMORPHISM, ORIENTAL 2

   HYPERTENSION, SALT-SENSITIVE ESSENTIAL, SUSCEPTIBILITY TO

       SKIN/HAIR/EYE PIGMENTATION 5, BLACK/NONBLACK HAIR

     SKIN/HAIR/EYE PIGMENTATION 5, DARK/FAIR SKIN, INCLUDED

     SKIN/HAIR/EYE PIGMENTATION 5, DARK/LIGHT EYES, INCLUDED

                B CELL-POSITIVE, NK CELL-POSITIVE

SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-
                         NEGATIVE,

                B CELL-POSITIVE, NK CELL-POSITIVE

SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-
                         NEGATIVE,

              ASTHMA, SUSCEPTIBILITY TO, INCLUDED
                    ATOPY, SUSCEPTIBILITY TO

        DERMATITIS, ATOPIC, 6, SUSCEPTIBILITY TO, INCLUDED

                                7

HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT
                            LOCUS

                 GMP REDUCTASE POLYMORPHISM

           PEPTIDE TRANSPORTER PSF2 POLYMORPHISM

            DIABETES MELLITUS, INSULIN-DEPENDENT, 5

     CORONARY ARTERY DISEASE, SUSCEPTIBILITY TO, INCLUDED

      CORONARY ARTERY SPASM, SUSCEPTIBILITY TO, INCLUDED

               PON1 ENZYME ACTIVITY, VARIATION IN

                 PHENYLTHIOCARBAMIDE TASTING

                 PHENYLTHIOCARBAMIDE TASTING

                       ACETYLATION, SLOW

HYPERCHOLESTEROLEMIA, FAMILIAL, DUE TO LDLR DEFECT, MODIFIER OF

  DIABETES MELLITUS, NONINSULIN-DEPENDENT, SUSCEPTIBILITY TO

  CORONARY HEART DISEASE IN FAMILIAL HYPERCHOLESTEROLEMIA,
                    PROTECTION AGAINST

  AMINOLEVULINATE DEHYDRATASE, ALAD*1/ALAD*2 POLYMORPHISM

                   PREECLAMPSIA/ECLAMPSIA 4

                   PREECLAMPSIA/ECLAMPSIA 4

        ANOREXIA NERVOSA, SUSCEPTIBILITY TO, 2, INCLUDED

    BIPOLAR AFFECTIVE DISORDER, SUSCEPTIBILITY TO, INCLUDED

         BULIMIA NERVOSA, SUSCEPTIBILITY TO, 2, INCLUDED

             MEMORY IMPAIRMENT, SUSCEPTIBILITY TO

 OBSESSIVE-COMPULSIVE DISORDER, PROTECTION AGAINST, INCLUDED

  PARKINSON DISEASE, AGE AT ONSET, SUSCEPTIBILITY TO, INCLUDED

                    COLON CANCER, SOMATIC

                ATOPIC ASTHMA, SUSCEPTIBILITY TO

                 ACTININ, ALPHA-3 POLYMORPHISM

                        ACTN3 DEFICIENCY
                        ACTN3 DEFICIENCY

                    SPRINTING PERFORMANCE

        SKIN/HAIR/EYE PIGMENTATION 10, BLOND/BROWN HAIR

             ALPHA-2-MACROGLOBULIN POLYMORPHISM

         ALZHEIMER DISEASE, SUSCEPTIBILITY TO, INCLUDED

           DIABETES MELLITUS, TYPE 1, SUSCEPTIBILITY TO

                MULTIPLE MYELOMA, RESISTANCE TO

                MULTIPLE MYELOMA, RESISTANCE TO

             CEREBRAL INFARCTION, SUSCEPTIBILITY TO

AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,
                      SUSCEPTIBILITY TO

             LUMBAR DISC DISEASE, SUSCEPTIBILITY TO

                 FAMILIAL MEDITERRANEAN FEVER

                   ASTHMA, SUSCEPTIBILITY TO

                      ATOPY, RESISTANCE TO

                        EAR WAX, WET/DRY

               BENZENE TOXICITY, SUSCEPTIBILITY TO

 BREAST CANCER, POST-CHEMOTHERAPY POOR SURVIVAL IN, INCLUDED

   LEUKEMIA, POST-CHEMOTHERAPY, SUSCEPTIBILITY TO, INCLUDED

 PLATELET-ENDOTHELIAL CELL ADHESION MOLECULE 1 POLYMORPHISM

              PARKINSON DISEASE, SUSCEPTIBILITY TO

               HEPATITIS B VIRUS, SUSCEPTIBILITY TO

               HEPATITIS B VIRUS, SUSCEPTIBILITY TO

               DEBRISOQUINE, POOR METABOLISM OF

         PYRUVATE DEHYDROGENASE E1-ALPHA DEFICIENCY
Coordinates               Genotype
Gene, amino acid change   Trait-associated allele
chr1:9246497              G/A
H6PD, R453Q               A
chr1:25589952             C/G
RHCE, P226A               C
chr1:46643348             C/A
FAAH, P129T               A
chr1:65809029             G/G
LEPR, K109R               G
chr1:65831101             G/G
LEPR, Q223R               G
chr1:167963570            G/A
SELE, H468Y               A
chr1:194925860            C/T
CFH, Y402H                C
chr1:194925860            C/T
CFH, Y402H                C
chr1:205173101            A/A
PIGR, A580V               A
chr1:224086256            T/C
EPHX1, Y113H              C
chr1:224086256            T/C
EPHX1, Y113H              C
chr1:224086256            T/C
EPHX1, Y113H              C
chr1:224086256            T/C
EPHX1, Y113H              C
chr2:108880033            G/G
EDAR, V370A               G
chr2:230758959            G/G
SP110, L425S              G
chr3:46374212             G/A
CCR2, V64I                A
chr4:2876505              T/T
ADD1, G460W               T
chr4:100458342            T/C
ADH1B, R48H               T
chr4:100458342            T/C
ADH1B, R48H               T
chr4:100479812            T/C
ADH1C, I350V              C
chr4:100482988            C/T
ADH1C, R272Q              T
chr4:102970099            G/A
BANK1, R61H               A
chr5:7923973              A/G
MTRR, I22M                G
chr5:7923973              A/G
MTRR, I22M                G
chr5:35896825             T/C
IL7R, T66I                T
chr5:35896825             T/C
IL7R, T66I                T
chr6:12404241             G/T
EDN1, K198N               T
chr6:12404241     G/T
EDN1, K198N       T
chr6:16398740     T/A
GMPR, F256I       A
chr6:32904729     T/C
TAP2, A665T       T
chr7:34784638     A/T
NPSR1, N107I      T
chr7:94784020     A/T
PON1, L55M        T
chr7:94784020     A/T
PON1, L55M        T
chr7:94784020     A/T
PON1, L55M        T
chr7:94872711     G/C
PON2, C311S       G
chr7:94878952     G/C
PON2, A148G       C
chr7:116986769    G/A
CFTR, M470V       G
chr7:141319073    T/C
TAS2R38, I296V    C
chr7:141319174    G/A
TAS2R38, V262A    G
chr7:141319814    C/G
TAS2R38, A49P     G
chr8:18302134     T/C
NAT2, I114T       C
chr8:18302596     G/A
NAT2, K268R       G
chr8:118253964    C/T
SLC30A8, R325W    T
chr8:133969434    T/G
TG, S734A         G
chr9:106660688    C/T
ABCA1, R219K      T
chr10:70311866    C/C
STOX1, Y153H      C
chr11:27636492    C/T
BDNF, V66M        T
chr11:27636492    C/T
BDNF, V66M        T
chr11:27636492    C/T
BDNF, V66M        T
chr11:27636492    C/T
BDNF, V66M        T
chr11:27636492    C/T
BDNF, V66M        T
chr11:27636492    C/T
BDNF, V66M        T
chr11:48101951    A/C
PTPRJ, Q276P      C
chr12:9123535     T/C
A2M, V1000I       T
chr12:9123535     T/C
A2M, V1000I       T
chr12:110726149   G/A
ALDH2, E504K      A
chr12:110726149   G/A
ALDH2, E504K      A
chr12:110726149   G/A
ALDH2, E504K      A
chr12:120779718   T/C
HPD, A33T         T
chr13:31804729    A/C
BRCA2, N372H      C
chr14:60993992    G/A
PRKCH, V374I      A
chr16:16159100    C/T
ABCC6, R1268Q     T
chr16:46815699    T/T
ABCC11, G180R     T
chr16:68302646    A/A
NQO1, P187S       A
chr16:68302646    A/A
NQO1, P187S       A
chr16:68302646    A/A
NQO1, P187S       A
chr16:88513441    G/A
MC1R, V92M        A
chr16:88513441    G/A
MC1R, V92M        A
chr17:5426091     A/T
NLRP1, L155H      T
chr17:39694471    T/C
SLC4A1, K56E      C
chr17:59804699    G/C
PECAM1, L125V     C
chr20:54394948    T/T
AURKA, F31I       T
chrX:19285703     A/C
PDHA1, M282L      C
                         Associated trait

               CORTISONE REDUCTASE DEFICIENCY

                     RH E/e POLYMORPHISM

               DRUG ADDICTION, SUSCEPTIBILITY TO

                LEPTIN RECEPTOR POLYMORPHISM

                LEPTIN RECEPTOR POLYMORPHISM

              IgA NEPHROPATHY, SUSCEPTIBILITY TO

                BASAL LAMINAR DRUSEN, INCLUDED

    MACULAR DEGENERATION, AGE-RELATED, 4, SUSCEPTIBILITY TO

              IgA NEPHROPATHY, SUSCEPTIBILITY TO

            EMPHYSEMA, SUSCEPTIBILITY TO, INCLUDED

       LYMPHOPROLIFERATIVE DISORDERS, SUSCEPTIBILITY TO

           PREECLAMPSIA, SUSCEPTIBILITY TO, INCLUDED

  PULMONARY DISEASE, CHRONIC OBSTRUCTIVE, SUSCEPTIBILITY TO,
                         INCLUDED

              HAIR MORPHOLOGY 1, HAIR THICKNESS

        MYCOBACTERIUM TUBERCULOSIS, SUSCEPTIBILITY TO

      HUMAN IMMUNODEFICIENCY VIRUS TYPE 1, RESISTANCE TO

   HYPERTENSION, SALT-SENSITIVE ESSENTIAL, SUSCEPTIBILITY TO

 AERODIGESTIVE TRACT CANCER, SQUAMOUS CELL, ALCOHOL-RELATED,
                 PROTECTION AGAINST; INCLUDED

           ALCOHOL DEPENDENCE, PROTECTION AGAINST

           ALCOHOL DEPENDENCE, PROTECTION AGAINST

           ALCOHOL DEPENDENCE, PROTECTION AGAINST

        SYSTEMIC LUPUS ERYTHMATOSUS, ASSOCIATION WITH

          DOWN SYNDROME, SUSCEPTIBILITY TO, INCLUDED

    NEURAL TUBE DEFECTS, FOLATE-SENSITIVE, SUSCEPTIBILITY TO

                B CELL-POSITIVE, NK CELL-POSITIVE

SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-
                         NEGATIVE,

                                7
HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT
                            LOCUS

                GMP REDUCTASE POLYMORPHISM

          PEPTIDE TRANSPORTER PSF2 POLYMORPHISM

                   ASTHMA SUSCEPTIBILITY 2

    CORONARY ARTERY DISEASE, SUSCEPTIBILITY TO, INCLUDED

MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 5,
                        INCLUDED

              PON1 ENZYME ACTIVITY, VARIATION IN

                PARAOXONASE 2 POLYMORPHISM

                PARAOXONASE 2 POLYMORPHISM

                     CFTR POLYMORPHISM

                PHENYLTHIOCARBAMIDE TASTING

                PHENYLTHIOCARBAMIDE TASTING

                PHENYLTHIOCARBAMIDE TASTING

                      ACETYLATION, SLOW

                      ACETYLATION, SLOW

 DIABETES MELLITUS, NONINSULIN-DEPENDENT, SUSCEPTIBILITY TO

       AUTOIMMUNE THYROID DISEASE, SUSCEPTIBILITY TO, 3

 CORONARY HEART DISEASE IN FAMILIAL HYPERCHOLESTEROLEMIA,
                   PROTECTION AGAINST

                  PREECLAMPSIA/ECLAMPSIA 4

       ANOREXIA NERVOSA, SUSCEPTIBILITY TO, 2, INCLUDED

   BIPOLAR AFFECTIVE DISORDER, SUSCEPTIBILITY TO, INCLUDED

        BULIMIA NERVOSA, SUSCEPTIBILITY TO, 2, INCLUDED

            MEMORY IMPAIRMENT, SUSCEPTIBILITY TO

OBSESSIVE-COMPULSIVE DISORDER, PROTECTION AGAINST, INCLUDED

 PARKINSON DISEASE, AGE AT ONSET, SUSCEPTIBILITY TO, INCLUDED

                   COLON CANCER, SOMATIC

            ALPHA-2-MACROGLOBULIN POLYMORPHISM

        ALZHEIMER DISEASE, SUSCEPTIBILITY TO, INCLUDED

                 ALCOHOL SENSITIVITY, ACUTE
                   ALCOHOL SENSITIVITY, ACUTE

             HANGOVER, SUSCEPTIBILITY TO, INCLUDED

SUBLINGUAL NITROGLYCERIN, SUSCEPTIBILITY TO POOR RESPONSE TO,
                          INCLUDED

                         HAWKINSINURIA

      BREAST-OVARIAN CANCER, FAMILIAL, SUSCEPTIBILITY TO, 2

             CEREBRAL INFARCTION, SUSCEPTIBILITY TO

                  PSEUDOXANTHOMA ELASTICUM

                        EAR WAX, WET/DRY

               BENZENE TOXICITY, SUSCEPTIBILITY TO

BREAST CANCER, POST-CHEMOTHERAPY POOR SURVIVAL IN, INCLUDED

   LEUKEMIA, POST-CHEMOTHERAPY, SUSCEPTIBILITY TO, INCLUDED

   SKIN/HAIR/EYE PIGMENTATION 2, BLOND HAIR/FAIR SKIN, INCLUDED

         SKIN/HAIR/EYE PIGMENTATION 2, RED HAIR/FAIR SKIN

VITILIGO-ASSOCIATED MULTIPLE AUTOIMMUNE DISEASE SUSCEPTIBILITY 1

                         BAND 3 MEMPHIS

 PLATELET-ENDOTHELIAL CELL ADHESION MOLECULE 1 POLYMORPHISM

                COLON CANCER, SUSCEPTIBILITY TO

         PYRUVATE DEHYDROGENASE E1-ALPHA DEFICIENCY
Coordinates               Genotype
Gene, amino acid change   Trait-associated allele
chr1:25589952             C/G
RHCE, P226A               C
chr1:65809029             G/G
LEPR, K109R               G
chr1:65831101             A/G
LEPR, Q223R               G
chr1:152693594            A/C
IL6R, D358A               C
chr1:159910422            T/C
FCGR2B, I232T             C
chr1:159910422            T/C
FCGR2B, I232T             C
chr1:221351222            T/C
TLR5, N592S               C
chr1:224086256            C/C
EPHX1, Y113H              C
chr1:224086256            C/C
EPHX1, Y113H              C
chr1:224086256            C/C
EPHX1, Y113H              C
chr1:224086256            C/C
EPHX1, Y113H              C
chr2:108880033            A/G
EDAR, V370A               G
chr2:218967976            G/A
SLC11A1, D543N            A
chr2:230758959            G/G
SP110, L425S              G
chr2:233848107            A/G
ATG16L1, T300A            G
chr2:234333883            A/A
UGT1A1, G71R              A
chr2:234333883            A/A
UGT1A1, G71R              A
chr4:2876505              T/T
ADD1, G460W               T
chr4:100458342            T/C
ADH1B, R48H               T
chr4:100458342            T/C
ADH1B, R48H               T
chr5:33999627             C/T
SLC45A2, E272K            T
chr5:33999627             C/T
SLC45A2, E272K            T
chr5:33999627             C/T
SLC45A2, E272K            T
chr5:35896825             T/C
IL7R, T66I                T
chr5:35896825             T/C
IL7R, T66I                T
chr5:35906947             G/A
IL7R, I138V               G
chr5:35906947             G/A
IL7R, I138V               G
chr5:147461148   A/G
SPINK5, E420K    A
chr5:147461148   A/G
SPINK5, E420K    A
chr5:147461148   A/G
SPINK5, E420K    A
chr5:148186666   G/C
ADRB2, Q27E      G
chr5:148186666   G/C
ADRB2, Q27E      G
chr5:148186666   G/C
ADRB2, Q27E      G
chr6:12404241    G/T
EDN1, K198N      T
chr6:12404241    G/T
EDN1, K198N      T
chr6:16398740    A/A
GMPR, F256I      A
chr6:32022159    G/A
CFB, R32Q        A
chr6:32904663    A/G
TAP2, Q687*      A
chr6:46780902    A/G
PLA2G7, A379V    A
chr7:34784638    A/T
NPSR1, N107I     T
chr7:94775382    T/C
PON1, Q192R      C
chr7:94775382    T/C
PON1, Q192R      C
chr7:94775382    T/C
PON1, Q192R      C
chr7:141319073   C/C
TAS2R38, I296V   C
chr7:141319814   G/G
TAS2R38, A49P    G
chr9:106660688   C/T
ABCA1, R219K     T
chr10:70311866   T/C
STOX1, Y153H     C
chr10:70315382   A/C
STOX1, E608D     C
chr11:27636492   C/T
BDNF, V66M       T
chr11:27636492   C/T
BDNF, V66M       T
chr11:27636492   C/T
BDNF, V66M       T
chr11:27636492   C/T
BDNF, V66M       T
chr11:27636492   C/T
BDNF, V66M       T
chr11:27636492   C/T
BDNF, V66M       T
chr11:48101951   A/C
PTPRJ, Q276P     C
chr11:66084671   T/C
ACTN3, R577*      T
chr11:66084671    T/C
ACTN3, R577*      T
chr11:66084671    T/C
ACTN3, R577*      T
chr12:9123535     T/C
A2M, V1000I       T
chr12:9123535     T/C
A2M, V1000I       T
chr12:110726149   G/A
ALDH2, E504K      A
chr12:110726149   G/A
ALDH2, E504K      A
chr12:110726149   G/A
ALDH2, E504K      A
chr13:31804729    A/C
BRCA2, N372H      C
chr15:25902148    C/T
OCA2, A481T       T
chr16:3647748     G/A
DNASE1, Q244R     G
chr16:46815699    T/T
ABCC11, G180R     T
chr17:19753133    T/C
AKAP10, I646V     C
chr17:71270708    G/A
GALK1, A198V      A
chr18:9107867     T/C
NDUFV2, A29V      T
chr20:54394948    A/T
AURKA, F31I       T
chr21:33536120    T/C
IFNAR2, S8F       T
chr22:29341610    G/C
TCN2, P259R       G
chr22:40856638    G/A
CYP2D6, P34S      A
                           Associated trait

                        RH E/e POLYMORPHISM

                  LEPTIN RECEPTOR POLYMORPHISM

                  LEPTIN RECEPTOR POLYMORPHISM

          INTERLEUKIN-6 SOLUBLE RECEPTOR, SERUM LEVEL OF

  MALARIA, RESISTANCE TO, INCLUDED SYSTEMIC LUPUS ERYTHEMATOSIS,
                    SUSCEPTIBILITY TO, INCLUDED

         SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO

               LEGIONNAIRE DISEASE, SUSCEPTIBILITY TO

              EMPHYSEMA, SUSCEPTIBILITY TO, INCLUDED

         LYMPHOPROLIFERATIVE DISORDERS, SUSCEPTIBILITY TO

             PREECLAMPSIA, SUSCEPTIBILITY TO, INCLUDED

PULMONARY DISEASE, CHRONIC OBSTRUCTIVE, SUSCEPTIBILITY TO, INCLUDED

                 HAIR MORPHOLOGY 1, HAIR THICKNESS

                  BURULI ULCER, SUSCEPTIBILITY TO

          MYCOBACTERIUM TUBERCULOSIS, SUSCEPTIBILITY TO

         INFLAMMATORY BOWEL DISEASE 10, SUSCEPTIBILITY TO

                         GILBERT SYNDROME

     HYPERBILIRUBINEMIA, TRANSIENT FAMILIAL NEONATAL, INCLUDED

     HYPERTENSION, SALT-SENSITIVE ESSENTIAL, SUSCEPTIBILITY TO

  AERODIGESTIVE TRACT CANCER, SQUAMOUS CELL, ALCOHOL-RELATED,
                  PROTECTION AGAINST; INCLUDED

             ALCOHOL DEPENDENCE, PROTECTION AGAINST

         SKIN/HAIR/EYE PIGMENTATION 5, BLACK/NONBLACK HAIR

       SKIN/HAIR/EYE PIGMENTATION 5, DARK/FAIR SKIN, INCLUDED

       SKIN/HAIR/EYE PIGMENTATION 5, DARK/LIGHT EYES, INCLUDED

                  B CELL-POSITIVE, NK CELL-POSITIVE

 SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-
                          NEGATIVE,

                  B CELL-POSITIVE, NK CELL-POSITIVE

 SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-
                          NEGATIVE,
                ASTHMA, SUSCEPTIBILITY TO, INCLUDED

                      ATOPY, SUSCEPTIBILITY TO

          DERMATITIS, ATOPIC, 6, SUSCEPTIBILITY TO, INCLUDED

          ASTHMA, CHILDHOOD, SUSCEPTIBILITY TO, INCLUDED

          METABOLIC SYNDROME, SUSCEPTIBILITY TO, INCLUDED

                     OBESITY, SUSCEPTIBILITY TO

                                  7

HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS

                   GMP REDUCTASE POLYMORPHISM

       MACULAR DEGENERATION, AGE-RELATED, REDUCED RISK OF

             PEPTIDE TRANSPORTER PSF2 POLYMORPHISM

                ASTHMA AND ATOPY, SUSCEPTIBILITY TO

                      ASTHMA SUSCEPTIBILITY 2

       CORONARY ARTERY DISEASE, SUSCEPTIBILITY TO, INCLUDED

        CORONARY ARTERY SPASM, SUSCEPTIBILITY TO, INCLUDED

                 PON1 ENZYME ACTIVITY, VARIATION IN

                   PHENYLTHIOCARBAMIDE TASTING

                   PHENYLTHIOCARBAMIDE TASTING

    CORONARY HEART DISEASE IN FAMILIAL HYPERCHOLESTEROLEMIA,
                      PROTECTION AGAINST

                     PREECLAMPSIA/ECLAMPSIA 4

                     PREECLAMPSIA/ECLAMPSIA 4

          ANOREXIA NERVOSA, SUSCEPTIBILITY TO, 2, INCLUDED

      BIPOLAR AFFECTIVE DISORDER, SUSCEPTIBILITY TO, INCLUDED

           BULIMIA NERVOSA, SUSCEPTIBILITY TO, 2, INCLUDED

               MEMORY IMPAIRMENT, SUSCEPTIBILITY TO

   OBSESSIVE-COMPULSIVE DISORDER, PROTECTION AGAINST, INCLUDED

    PARKINSON DISEASE, AGE AT ONSET, SUSCEPTIBILITY TO, INCLUDED

                      COLON CANCER, SOMATIC

                   ACTININ, ALPHA-3 POLYMORPHISM
                ACTININ, ALPHA-3 POLYMORPHISM

                      ACTN3 DEFICIENCY

                   SPRINTING PERFORMANCE

            ALPHA-2-MACROGLOBULIN POLYMORPHISM

        ALZHEIMER DISEASE, SUSCEPTIBILITY TO, INCLUDED

                  ALCOHOL SENSITIVITY, ACUTE

            HANGOVER, SUSCEPTIBILITY TO, INCLUDED

SUBLINGUAL NITROGLYCERIN, SUSCEPTIBILITY TO POOR RESPONSE TO,
                          INCLUDED

     BREAST-OVARIAN CANCER, FAMILIAL, SUSCEPTIBILITY TO, 2

              ALBINISM, OCULOCUTANEOUS, TYPE II

      SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO

                      EAR WAX, WET/DRY

        CARDIAC CONDUCTION DEFECT, SUSCEPTIBILITY TO

                  GALACTOKINASE DEFICIENCY

            PARKINSON DISEASE, SUSCEPTIBILITY TO

               COLON CANCER, SUSCEPTIBILITY TO

             HEPATITIS B VIRUS, SUSCEPTIBILITY TO

                     TCN2 POLYMORPHISM

             DEBRISOQUINE, POOR METABOLISM OF
Coordinates               Genotype
Gene, amino acid change   Trait-associated allele
chr1:25589952             C/G
RHCE, P226A               C
chr1:46643348             C/A
FAAH, P129T               A
chr1:65809029             G/G
LEPR, K109R               G
chr1:65831101             G/G
LEPR, Q223R               G
chr1:152693594            A/C
IL6R, D358A               C
chr1:167963570            G/A
SELE, H468Y               A
chr1:169346704            A/A
FMO3, V257M               A
chr1:221351222            T/C
TLR5, N592S               C
chr1:224086256            T/C
EPHX1, Y113H              C
chr1:224086256            T/C
EPHX1, Y113H              C
chr1:224086256            T/C
EPHX1, Y113H              C
chr1:224086256            T/C
EPHX1, Y113H              C
chr2:230758959            G/G
SP110, L425S              G
chr2:233848107            A/G
ATG16L1, T300A            G
chr3:10306457             G/T
GHRL, L72M                T
chr3:10306457             G/T
GHRL, L72M                T
chr3:46374212             G/A
CCR2, V64I                A
chr4:2876505              G/T
ADD1, G460W               T
chr4:5693417              G/A
EVC2, R399*               A
chr5:74020971             A/G
HEXB, K121R               G
chr6:12404241             G/T
EDN1, K198N               T
chr6:12404241             G/T
EDN1, K198N               T
chr6:16398740             A/A
GMPR, F256I               A
chr6:32904729             T/C
TAP2, A665T               T
chr6:149763383            G/A
SUMO4, M55V               G
chr7:34784638             A/T
NPSR1, N107I              T
chr7:94775382             T/C
PON1, Q192R               C
chr7:94775382     T/C
PON1, Q192R       C
chr7:94775382     T/C
PON1, Q192R       C
chr7:116986769    G/A
CFTR, M470V       G
chr7:141319174    G/A
TAS2R38, V262A    G
chr7:141319814    G/G
TAS2R38, A49P     G
chr8:18302383     G/A
NAT2, R197Q       A
chr8:118253964    C/T
SLC30A8, R325W    T
chr8:133969434    T/G
TG, S734A         G
chr9:106660688    T/T
ABCA1, R219K      T
chr10:70311866    C/C
STOX1, Y153H      C
chr10:75343107    T/C
PLAU, P141L       T
chr11:27636492    C/T
BDNF, V66M        T
chr11:27636492    C/T
BDNF, V66M        T
chr11:27636492    C/T
BDNF, V66M        T
chr11:27636492    C/T
BDNF, V66M        T
chr11:27636492    C/T
BDNF, V66M        T
chr11:27636492    C/T
BDNF, V66M        T
chr11:48101951    A/C
PTPRJ, Q276P      C
chr12:120779718   T/C
HPD, A33T         T
chr16:3647748     G/A
DNASE1, Q244R     G
chr16:46815699    T/T
ABCC11, G180R     T
chr16:68302646    A/A
NQO1, P187S       A
chr16:68302646    A/A
NQO1, P187S       A
chr16:68302646    A/A
NQO1, P187S       A
chr17:35133114    A/G
ERBB2, V655I      A
chr17:59804699    G/C
PECAM1, L125V     C
chr21:33562658    A/G
IL10RB, E47K      A
chr22:49411282    C/C
ARSA, N350S       C
                           Associated trait

                        RH E/e POLYMORPHISM

                 DRUG ADDICTION, SUSCEPTIBILITY TO

                  LEPTIN RECEPTOR POLYMORPHISM

                  LEPTIN RECEPTOR POLYMORPHISM

          INTERLEUKIN-6 SOLUBLE RECEPTOR, SERUM LEVEL OF

                 IgA NEPHROPATHY, SUSCEPTIBILITY TO

                         TRIMETHYLAMINURIA

               LEGIONNAIRE DISEASE, SUSCEPTIBILITY TO

              EMPHYSEMA, SUSCEPTIBILITY TO, INCLUDED

         LYMPHOPROLIFERATIVE DISORDERS, SUSCEPTIBILITY TO

             PREECLAMPSIA, SUSCEPTIBILITY TO, INCLUDED

PULMONARY DISEASE, CHRONIC OBSTRUCTIVE, SUSCEPTIBILITY TO, INCLUDED

          MYCOBACTERIUM TUBERCULOSIS, SUSCEPTIBILITY TO

         INFLAMMATORY BOWEL DISEASE 10, SUSCEPTIBILITY TO

          METABOLIC SYNDROME, SUSCEPTIBILITY TO, INCLUDED

                      OBESITY, AGE AT ONSET OF

        HUMAN IMMUNODEFICIENCY VIRUS TYPE 1, RESISTANCE TO

      HYPERTENSION, SALT-SENSITIVE ESSENTIAL, SUSCEPTIBILITY TO

                    ELLIS-VAN CREVELD SYNDROME

                        HEXB POLYMORPHISM

                                  7

HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS

                   GMP REDUCTASE POLYMORPHISM

              PEPTIDE TRANSPORTER PSF2 POLYMORPHISM

               DIABETES MELLITUS, INSULIN-DEPENDENT, 5

                      ASTHMA SUSCEPTIBILITY 2

       CORONARY ARTERY DISEASE, SUSCEPTIBILITY TO, INCLUDED
             CORONARY ARTERY SPASM, SUSCEPTIBILITY TO, INCLUDED

                      PON1 ENZYME ACTIVITY, VARIATION IN

                             CFTR POLYMORPHISM

                        PHENYLTHIOCARBAMIDE TASTING

                        PHENYLTHIOCARBAMIDE TASTING

                              ACETYLATION, SLOW

         DIABETES MELLITUS, NONINSULIN-DEPENDENT, SUSCEPTIBILITY TO

              AUTOIMMUNE THYROID DISEASE, SUSCEPTIBILITY TO, 3

CORONARY HEART DISEASE IN FAMILIAL HYPERCHOLESTEROLEMIA, PROTECTION AGAINST

                          PREECLAMPSIA/ECLAMPSIA 4

               ALZHEIMER DISEASE, LATE-ONSET, SUSCEPTIBILITY TO

               ANOREXIA NERVOSA, SUSCEPTIBILITY TO, 2, INCLUDED

           BIPOLAR AFFECTIVE DISORDER, SUSCEPTIBILITY TO, INCLUDED

                BULIMIA NERVOSA, SUSCEPTIBILITY TO, 2, INCLUDED

                    MEMORY IMPAIRMENT, SUSCEPTIBILITY TO

        OBSESSIVE-COMPULSIVE DISORDER, PROTECTION AGAINST, INCLUDED

         PARKINSON DISEASE, AGE AT ONSET, SUSCEPTIBILITY TO, INCLUDED

                           COLON CANCER, SOMATIC

                                HAWKINSINURIA

              SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO

                              EAR WAX, WET/DRY

                     BENZENE TOXICITY, SUSCEPTIBILITY TO

       BREAST CANCER, POST-CHEMOTHERAPY POOR SURVIVAL IN, INCLUDED

          LEUKEMIA, POST-CHEMOTHERAPY, SUSCEPTIBILITY TO, INCLUDED

                             ERBB2 POLYMORPHISM

        PLATELET-ENDOTHELIAL CELL ADHESION MOLECULE 1 POLYMORPHISM

                     HEPATITIS B VIRUS, SUSCEPTIBILITY TO

                       ARYLSULFATASE A POLYMORPHISM
Coordinates               Genotype
Gene, amino acid change   Trait-associated allele
chr1:9246497              G/A
H6PD, R453Q               A
chr1:25589952             C/G
RHCE, P226A               C
chr1:65809029             A/G
LEPR, K109R               G
chr1:65831101             A/G
LEPR, Q223R               G
chr1:65848540             G/C
LEPR, K656N               C
chr1:152693594            C/C
IL6R, D358A               C
chr1:169346704            G/A
FMO3, V257M               A
chr1:180821180            C/T
RNASEL, R462Q             T
chr1:194908856            G/A
CFH, I62V                 G
chr1:201460809            C/T
CHIT1, G102S              T
chr1:221351222            T/C
TLR5, N592S               C
chr1:224086256            T/C
EPHX1, Y113H              C
chr1:224086256            T/C
EPHX1, Y113H              C
chr1:224086256            T/C
EPHX1, Y113H              C
chr1:224086256            T/C
EPHX1, Y113H              C
chr2:108880033            G/G
EDAR, V370A               G
chr2:230758959            G/G
SP110, L425S              G
chr3:46374212             G/A
CCR2, V64I                A
chr3:46390065             G/A
CCR5, R223Q               A
chr4:2876505              T/T
ADD1, G460W               T
chr5:33999627             T/T
SLC45A2, E272K            T
chr5:33999627             T/T
SLC45A2, E272K            T
chr5:33999627             T/T
SLC45A2, E272K            T
chr5:35896825             T/C
IL7R, T66I                T
chr5:35896825             T/C
IL7R, T66I                T
chr5:35906947             G/A
IL7R, I138V               G
chr5:35906947             G/A
IL7R, I138V       G
chr5:74020971     A/G
HEXB, K121R       G
chr5:148186633    G/A
ADRB2, R16G       G
chr5:148186633    G/A
ADRB2, R16G       G
chr5:169743374    C/T
KCNMB1, E65K      T
chr6:16398740     A/A
GMPR, F256I       A
chr6:46787262     A/G
PLA2G7, I198T     G
chr6:149763383    G/A
SUMO4, M55V       G
chr7:34784638     T/T
NPSR1, N107I      T
chr7:94775382     C/C
PON1, Q192R       C
chr7:94775382     C/C
PON1, Q192R       C
chr7:94775382     C/C
PON1, Q192R       C
chr7:94872711     G/C
PON2, C311S       G
chr7:94878952     G/C
PON2, A148G       C
chr7:116986769    G/A
CFTR, M470V       G
chr7:117015110    A/G
CFTR, I556V       G
chr7:141319073    C/C
TAS2R38, I296V    C
chr7:141319814    G/G
TAS2R38, A49P     G
chr8:18302383     G/A
NAT2, R197Q       A
chr8:118253964    C/T
SLC30A8, R325W    T
chr8:133969434    G/G
TG, S734A         G
chr9:106660688    C/T
ABCA1, R219K      T
chr10:64085190    A/G
ZNF365, A62T      A
chr10:70311866    C/C
STOX1, Y153H      C
chr12:111833253   G/A
OAS1, S162G       G
chr13:107661592   G/A
LIG4, T9I         A
chr14:20010446    G/A
NP, S51G          G
chr15:63281265    A/G
CILP, I395T       G
chr16:27281681    T/C
IL4R, S503P       C
chr16:27281681   T/C
IL4R, S503P      C
chr16:46815699   T/T
ABCC11, G180R    T
chr16:68302646   G/A
NQO1, P187S      A
chr16:68302646   G/A
NQO1, P187S      A
chr16:68302646   G/A
NQO1, P187S      A
chr17:7520197    G/C
TP53, P72R       C
chr17:39694471   T/C
SLC4A1, K56E     C
chr17:59804699   G/C
PECAM1, L125V    C
chr20:54394948   A/T
AURKA, F31I      T
chr21:33562658   A/G
IL10RB, E47K     A
chr22:17281004   C/T
PRODH, Q521R     C
chr22:17281004   C/T
PRODH, Q521R     C
chr22:40856638   G/A
CYP2D6, P34S     A
                              Associated trait


                    CORTISONE REDUCTASE DEFICIENCY

                          RH E/e POLYMORPHISM

                     LEPTIN RECEPTOR POLYMORPHISM

                     LEPTIN RECEPTOR POLYMORPHISM

                     LEPTIN RECEPTOR POLYMORPHISM

            INTERLEUKIN-6 SOLUBLE RECEPTOR, SERUM LEVEL OF

                           TRIMETHYLAMINURIA

                  PROSTATE CANCER, SUSCEPTIBILITY TO

        MACULAR DEGENERATION, AGE-RELATED, 4, SUSCEPTIBILITY TO

                       CHITOTRIOSIDASE DEFICIENCY

                 LEGIONNAIRE DISEASE, SUSCEPTIBILITY TO

                 EMPHYSEMA, SUSCEPTIBILITY TO, INCLUDED

           LYMPHOPROLIFERATIVE DISORDERS, SUSCEPTIBILITY TO

               PREECLAMPSIA, SUSCEPTIBILITY TO, INCLUDED

  PULMONARY DISEASE, CHRONIC OBSTRUCTIVE, SUSCEPTIBILITY TO, INCLUDED

                   HAIR MORPHOLOGY 1, HAIR THICKNESS

            MYCOBACTERIUM TUBERCULOSIS, SUSCEPTIBILITY TO

          HUMAN IMMUNODEFICIENCY VIRUS TYPE 1, RESISTANCE TO

                     CCR5 POLYMORPHISM, ORIENTAL 2

        HYPERTENSION, SALT-SENSITIVE ESSENTIAL, SUSCEPTIBILITY TO

           SKIN/HAIR/EYE PIGMENTATION 5, BLACK/NONBLACK HAIR

          SKIN/HAIR/EYE PIGMENTATION 5, DARK/FAIR SKIN, INCLUDED

         SKIN/HAIR/EYE PIGMENTATION 5, DARK/LIGHT EYES, INCLUDED

                    B CELL-POSITIVE, NK CELL-POSITIVE

SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE,

                    B CELL-POSITIVE, NK CELL-POSITIVE

SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE,
SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE,

                          HEXB POLYMORPHISM

                 ASTHMA, NOCTURNAL, SUSCEPTIBILITY TO

            METABOLIC SYNDROME, SUSCEPTIBILITY TO, INCLUDED

                HYPERTENSION, DIASTOLIC, RESISTANCE TO

                     GMP REDUCTASE POLYMORPHISM

                  ASTHMA AND ATOPY, SUSCEPTIBILITY TO

                DIABETES MELLITUS, INSULIN-DEPENDENT, 5

                        ASTHMA SUSCEPTIBILITY 2

         CORONARY ARTERY DISEASE, SUSCEPTIBILITY TO, INCLUDED

          CORONARY ARTERY SPASM, SUSCEPTIBILITY TO, INCLUDED

                   PON1 ENZYME ACTIVITY, VARIATION IN

                     PARAOXONASE 2 POLYMORPHISM

                     PARAOXONASE 2 POLYMORPHISM

                           CFTR POLYMORPHISM

                             CYSTIC FIBROSIS

                     PHENYLTHIOCARBAMIDE TASTING

                     PHENYLTHIOCARBAMIDE TASTING

                           ACETYLATION, SLOW

       DIABETES MELLITUS, NONINSULIN-DEPENDENT, SUSCEPTIBILITY TO

            AUTOIMMUNE THYROID DISEASE, SUSCEPTIBILITY TO, 3

 CORONARY HEART DISEASE IN FAMILIAL HYPERCHOLESTEROLEMIA, PROTECTION
                               AGAINST

              URIC ACID NEPHROLITHIASIS, SUSCEPTIBILITY TO

                       PREECLAMPSIA/ECLAMPSIA 4

               DIABETES MELLITUS, TYPE 1, SUSCEPTIBILITY TO

                    MULTIPLE MYELOMA, RESISTANCE TO

               NUCLEOSIDE PHOSPHORYLASE POLYMORPHISM

                 LUMBAR DISC DISEASE, SUSCEPTIBILITY TO

                        ASTHMA, SUSCEPTIBILITY TO
                    ATOPY, RESISTANCE TO

                     EAR WAX, WET/DRY

             BENZENE TOXICITY, SUSCEPTIBILITY TO

BREAST CANCER, POST-CHEMOTHERAPY POOR SURVIVAL IN, INCLUDED

  LEUKEMIA, POST-CHEMOTHERAPY, SUSCEPTIBILITY TO, INCLUDED

                  CODON 72 POLYMORPHISM

                       BAND 3 MEMPHIS

PLATELET-ENDOTHELIAL CELL ADHESION MOLECULE 1 POLYMORPHISM

              COLON CANCER, SUSCEPTIBILITY TO

             HEPATITIS B VIRUS, SUSCEPTIBILITY TO

                  HYPERPROLINEMIA, TYPE I

        SCHIZOPHRENIA, SUSCEPTIBILITY TO, 4, INCLUDED

             DEBRISOQUINE, POOR METABOLISM OF
      Coordinates                Genotype
Gene, amino acid change   Trait-associated allele
      chr1:9246497                  A/A
     H6PD, R453Q                     A
     chr1:46643348                 C/A
      FAAH, P129T                    A
     chr1:65809029                 G/G
     LEPR, K109R                     G
     chr1:65831101                 G/G
     LEPR, Q223R                     G
    chr1:152693594                 A/C
      IL6R, D358A                    C
    chr1:167963570                 G/A
      SELE, H468Y                    A
    chr1:169346704                 G/A
     FMO3, V257M                     A
    chr1:180821180                  C/T
   RNASEL, R462Q                     T
    chr1:194908856                 G/A
        CFH, I62V                    G
    chr1:221351222                 C/C
      TLR5, N592S                    C
    chr1:224086256                  T/C
    EPHX1, Y113H                     C
    chr1:224086256                  T/C
    EPHX1, Y113H                     C
    chr1:224086256                  T/C
    EPHX1, Y113H                     C
    chr1:224086256                  T/C
    EPHX1, Y113H                     C
    chr2:108880033                 A/G
     EDAR, V370A                     G
    chr2:230758959                 G/G
     SP110, L425S                    G
    chr2:233848107                 A/G
   ATG16L1, T300A                    G
    chr2:234333883                 G/A
    UGT1A1, G71R                     A
    chr2:234333883                 G/A
    UGT1A1, G71R                     A
     chr3:46374212                  A/A
       CCR2, V64I                    A
    chr4:100458342                  T/C
     ADH1B, R48H                     T
    chr4:100458342                  T/C
     ADH1B, R48H                     T
    chr4:100479812                  T/C
     ADH1C, I350V                    C
    chr4:100482988                  C/T
    ADH1C, R272Q                     T
     chr5:35896825                  T/C
        IL7R, T66I                   T
     chr5:35896825                  T/C
        IL7R, T66I                   T
     chr5:35906947                 G/A
       IL7R, I138V                   G
     chr5:35906947                 G/A
       IL7R, I138V                   G
     chr6:16398740                  T/A
      GMPR, F256I                    A
  chr6:36759949   A/A
 CDKN1A, S31R      A
  chr6:46780902   A/G
 PLA2G7, A379V     A
 chr6:149763383   G/A
 SUMO4, M55V       G
  chr7:34784638   A/T
  NPSR1, N107I     T
  chr7:94775382   T/C
  PON1, Q192R      C
  chr7:94775382   T/C
  PON1, Q192R      C
  chr7:94775382   T/C
  PON1, Q192R      C
  chr7:94872711   G/C
  PON2, C311S      G
  chr7:94878952   G/C
  PON2, A148G      C
 chr7:141319174   G/A
TAS2R38, V262A     G
  chr8:18302650   G/A
  NAT2, G286E      A
  chr8:55701948   A/T
   RP1, N985Y      T
 chr8:118253964   T/T
SLC30A8, R325W     T
 chr8:133969434   G/G
    TG, S734A      G
 chr9:106660688   C/T
 ABCA1, R219K      T
 chr10:13192406   T/A
   OPTN, M98K      A
 chr10:13192406   T/A
   OPTN, M98K      A
 chr10:70311866   C/C
 STOX1, Y153H      C
 chr11:17366148   T/C
 KCNJ11, E23K      T
 chr11:27636492   C/T
   BDNF, V66M      T
 chr11:27636492   C/T
   BDNF, V66M      T
 chr11:27636492   C/T
   BDNF, V66M      T
 chr11:27636492   C/T
   BDNF, V66M      T
 chr11:27636492   C/T
   BDNF, V66M      T
 chr11:27636492   C/T
   BDNF, V66M      T
 chr11:59619680   A/G
 MS4A2, E237G      G
 chr11:66084671   T/C
  ACTN3, R577*     T
 chr11:66084671   T/C
  ACTN3, R577*     T
 chr11:66084671   T/C
  ACTN3, R577*     T
  chr12:9123535   T/C
   A2M, V1000I     T
  chr12:9123535   T/C
   A2M, V1000I     T
 chr12:14884706   C/T
  ART4, N265D      C
chr12:111833253   G/A
  OAS1, S162G      G
 chr14:20010446   G/A
    NP, S51G       G
 chr15:48665922   G/A
 TRPM7, T1482I     A
 chr15:63281265   A/G
   CILP, I395T     G
  chr16:3647748   G/A
DNASE1, Q244R      G
 chr16:46815699   T/T
ABCC11, G180R      T
 chr16:68302646   G/A
  NQO1, P187S      A
 chr16:68302646   G/A
  NQO1, P187S      A
 chr16:68302646   G/A
  NQO1, P187S      A
 chr17:59804699   G/C
PECAM1, L125V      C
  chr18:9107867   T/C
 NDUFV2, A29V      T
 chr20:54394948   A/T
  AURKA, F31I      T
                      Associated trait

             CORTISONE REDUCTASE DEFICIENCY

            DRUG ADDICTION, SUSCEPTIBILITY TO

              LEPTIN RECEPTOR POLYMORPHISM

              LEPTIN RECEPTOR POLYMORPHISM

      INTERLEUKIN-6 SOLUBLE RECEPTOR, SERUM LEVEL OF

            IgA NEPHROPATHY, SUSCEPTIBILITY TO

                   TRIMETHYLAMINURIA

            PROSTATE CANCER, SUSCEPTIBILITY TO

 MACULAR DEGENERATION, AGE-RELATED, 4, SUSCEPTIBILITY TO

          LEGIONNAIRE DISEASE, SUSCEPTIBILITY TO

          EMPHYSEMA, SUSCEPTIBILITY TO, INCLUDED

     LYMPHOPROLIFERATIVE DISORDERS, SUSCEPTIBILITY TO

         PREECLAMPSIA, SUSCEPTIBILITY TO, INCLUDED

PULMONARY DISEASE, CHRONIC OBSTRUCTIVE, SUSCEPTIBILITY TO,
                        INCLUDED
           HAIR MORPHOLOGY 1, HAIR THICKNESS

      MYCOBACTERIUM TUBERCULOSIS, SUSCEPTIBILITY TO

     INFLAMMATORY BOWEL DISEASE 10, SUSCEPTIBILITY TO

                    GILBERT SYNDROME

HYPERBILIRUBINEMIA, TRANSIENT FAMILIAL NEONATAL, INCLUDED

   HUMAN IMMUNODEFICIENCY VIRUS TYPE 1, RESISTANCE TO

  AERODIGESTIVE TRACT CANCER, SQUAMOUS CELL, ALCOHOL-
          RELATED, PROTECTION AGAINST; INCLUDED
        ALCOHOL DEPENDENCE, PROTECTION AGAINST

        ALCOHOL DEPENDENCE, PROTECTION AGAINST

        ALCOHOL DEPENDENCE, PROTECTION AGAINST

             B CELL-POSITIVE, NK CELL-POSITIVE

SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T
                      CELL-NEGATIVE,
             B CELL-POSITIVE, NK CELL-POSITIVE

SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T
                      CELL-NEGATIVE,
              GMP REDUCTASE POLYMORPHISM
       CIP1/WAF1 TUMOR-ASSOCIATED POLYMORPHISM 1

           ASTHMA AND ATOPY, SUSCEPTIBILITY TO

          DIABETES MELLITUS, INSULIN-DEPENDENT, 5

                  ASTHMA SUSCEPTIBILITY 2

   CORONARY ARTERY DISEASE, SUSCEPTIBILITY TO, INCLUDED

    CORONARY ARTERY SPASM, SUSCEPTIBILITY TO, INCLUDED

            PON1 ENZYME ACTIVITY, VARIATION IN

              PARAOXONASE 2 POLYMORPHISM

              PARAOXONASE 2 POLYMORPHISM

               PHENYLTHIOCARBAMIDE TASTING

                    ACETYLATION, SLOW

          HYPERTRIGLYCERIDEMIA, SUSCEPTIBILITY TO

DIABETES MELLITUS, NONINSULIN-DEPENDENT, SUSCEPTIBILITY TO

     AUTOIMMUNE THYROID DISEASE, SUSCEPTIBILITY TO, 3

CORONARY HEART DISEASE IN FAMILIAL HYPERCHOLESTEROLEMIA,
                    PROTECTION AGAINST
           GLAUCOMA 1, OPEN ANGLE, E, INCLUDED

       GLAUCOMA, NORMAL TENSION, SUSCEPTIBILITY TO

                 PREECLAMPSIA/ECLAMPSIA 4

DIABETES MELLITUS, NONINSULIN-DEPENDENT, SUSCEPTIBILITY TO

     ANOREXIA NERVOSA, SUSCEPTIBILITY TO, 2, INCLUDED

  BIPOLAR AFFECTIVE DISORDER, SUSCEPTIBILITY TO, INCLUDED

      BULIMIA NERVOSA, SUSCEPTIBILITY TO, 2, INCLUDED

           MEMORY IMPAIRMENT, SUSCEPTIBILITY TO

   OBSESSIVE-COMPULSIVE DISORDER, PROTECTION AGAINST,
                         INCLUDED
PARKINSON DISEASE, AGE AT ONSET, SUSCEPTIBILITY TO, INCLUDED

             ATOPIC ASTHMA, SUSCEPTIBILITY TO

              ACTININ, ALPHA-3 POLYMORPHISM

                     ACTN3 DEFICIENCY

                  SPRINTING PERFORMANCE

          ALPHA-2-MACROGLOBULIN POLYMORPHISM

       ALZHEIMER DISEASE, SUSCEPTIBILITY TO, INCLUDED
     ALZHEIMER DISEASE, SUSCEPTIBILITY TO, INCLUDED

                DOMBROCK BLOOD GROUP

       DIABETES MELLITUS, TYPE 1, SUSCEPTIBILITY TO

       NUCLEOSIDE PHOSPHORYLASE POLYMORPHISM

AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA
              COMPLEX 1, SUSCEPTIBILITY TO
         LUMBAR DISC DISEASE, SUSCEPTIBILITY TO

    SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO

                   EAR WAX, WET/DRY

           BENZENE TOXICITY, SUSCEPTIBILITY TO

 BREAST CANCER, POST-CHEMOTHERAPY POOR SURVIVAL IN,
                        INCLUDED
LEUKEMIA, POST-CHEMOTHERAPY, SUSCEPTIBILITY TO, INCLUDED

    PLATELET-ENDOTHELIAL CELL ADHESION MOLECULE 1
                     POLYMORPHISM
          PARKINSON DISEASE, SUSCEPTIBILITY TO

            COLON CANCER, SUSCEPTIBILITY TO
Coordinates               Genotype
Gene, amino acid change   Trait-associated allele
chr1:9246497              A/A
H6PD, R453Q               A
chr1:46643348             C/A
FAAH, P129T               A
chr1:65809029             G/G
LEPR, K109R               G
chr1:65831101             G/G
LEPR, Q223R               G
chr1:201460809            C/T
CHIT1, G102S              T
chr1:205173101            G/A
PIGR, A580V               A
chr1:221351222            T/C
TLR5, N592S               C
chr1:224086256            C/C
EPHX1, Y113H              C
chr1:224086256            C/C
EPHX1, Y113H              C
chr1:224086256            C/C
EPHX1, Y113H              C
chr1:224086256            C/C
EPHX1, Y113H              C
chr2:49043425             C/T
FSHR, N680S               C
chr2:49043425             C/T
FSHR, N680S               C
chr2:49044545             C/T
FSHR, T307A               C
chr2:74613333             G/A
HTRA2, G399S              A
chr2:108880033            G/G
EDAR, V370A               G
chr2:230758959            G/G
SP110, L425S              G
chr2:233848107            A/G
ATG16L1, T300A            G
chr3:46374212             G/A
CCR2, V64I                A
chr3:123486447            G/T
CASR, A986S               T
chr4:2876505              T/T
ADD1, G460W               T
chr4:100458342            T/C
ADH1B, R48H               T
chr4:100458342            T/C
ADH1B, R48H               T
chr5:7923973              A/G
MTRR, I22M                G
chr5:7923973              A/G
MTRR, I22M                G
chr5:33999627             C/T
SLC45A2, E272K            T
chr5:33999627             C/T
SLC45A2, E272K            T
chr5:33999627     C/T
SLC45A2, E272K    T
chr5:169743374    C/T
KCNMB1, E65K      T
chr6:16398740     A/A
GMPR, F256I       A
chr6:38758606     T/G
GLO1, A111E       T
chr6:46780902     A/G
PLA2G7, A379V     A
chr7:34784638     A/T
NPSR1, N107I      T
chr7:94775382     C/C
PON1, Q192R       C
chr7:94775382     C/C
PON1, Q192R       C
chr7:94775382     C/C
PON1, Q192R       C
chr7:116986769    G/A
CFTR, M470V       G
chr7:141319073    T/C
TAS2R38, I296V    C
chr7:141319174    G/A
TAS2R38, V262A    G
chr7:141319814    C/G
TAS2R38, A49P     G
chr8:18302383     G/A
NAT2, R197Q       A
chr8:27429782     G/A
EPHX2, R287Q      A
chr8:133969434    T/G
TG, S734A         G
chr9:106660688    T/T
ABCA1, R219K      T
chr9:115193712    C/G
ALAD, K59N        G
chr10:70311866    C/C
STOX1, Y153H      C
chr11:17366148    T/C
KCNJ11, E23K      T
chr11:27636492    C/T
BDNF, V66M        T
chr11:27636492    C/T
BDNF, V66M        T
chr11:27636492    C/T
BDNF, V66M        T
chr11:27636492    C/T
BDNF, V66M        T
chr11:27636492    C/T
BDNF, V66M        T
chr11:27636492    C/T
BDNF, V66M        T
chr11:48101951    A/C
PTPRJ, Q276P      C
chr11:68611939    A/A
TPCN2, G734E      A
chr11:112776038   A/A
ANKK1, E713K      A
chr12:111833253   G/A
OAS1, S162G       G
chr14:60993992    G/A
PRKCH, V374I      A
chr16:27281901    G/G
IL4R, Q576R       G
chr16:46815699    T/T
ABCC11, G180R     T
chr17:59804699    G/C
PECAM1, L125V     C
chr20:3141842     C/A
ITPA, P32T        A
chr20:54394948    A/T
AURKA, F31I       T
chr21:33562658    A/G
IL10RB, E47K      A
chr22:29341610    G/C
TCN2, P259R       G
chrX:19285703     A/C
PDHA1, M282L      C
                                  Associated trait

                        CORTISONE REDUCTASE DEFICIENCY

                        DRUG ADDICTION, SUSCEPTIBILITY TO

                         LEPTIN RECEPTOR POLYMORPHISM

                         LEPTIN RECEPTOR POLYMORPHISM

                           CHITOTRIOSIDASE DEFICIENCY

                       IgA NEPHROPATHY, SUSCEPTIBILITY TO

                     LEGIONNAIRE DISEASE, SUSCEPTIBILITY TO

                     EMPHYSEMA, SUSCEPTIBILITY TO, INCLUDED

               LYMPHOPROLIFERATIVE DISORDERS, SUSCEPTIBILITY TO

                   PREECLAMPSIA, SUSCEPTIBILITY TO, INCLUDED

      PULMONARY DISEASE, CHRONIC OBSTRUCTIVE, SUSCEPTIBILITY TO, INCLUDED

     OVARIAN HYPERSTIMULATION SYNDROME, MODIFIER OF SEVERITY OF, INCLUDED

                      OVARIAN RESPONSE TO FSH STIMULATION

                      OVARIAN RESPONSE TO FSH STIMULATION

                              PARKINSON DISEASE 13

                       HAIR MORPHOLOGY 1, HAIR THICKNESS

                 MYCOBACTERIUM TUBERCULOSIS, SUSCEPTIBILITY TO

                INFLAMMATORY BOWEL DISEASE 10, SUSCEPTIBILITY TO

              HUMAN IMMUNODEFICIENCY VIRUS TYPE 1, RESISTANCE TO

                            CALCIUM, SERUM LEVEL OF

            HYPERTENSION, SALT-SENSITIVE ESSENTIAL, SUSCEPTIBILITY TO

AERODIGESTIVE TRACT CANCER, SQUAMOUS CELL, ALCOHOL-RELATED, PROTECTION AGAINST;
                                  INCLUDED

                   ALCOHOL DEPENDENCE, PROTECTION AGAINST

                  DOWN SYNDROME, SUSCEPTIBILITY TO, INCLUDED

            NEURAL TUBE DEFECTS, FOLATE-SENSITIVE, SUSCEPTIBILITY TO

                SKIN/HAIR/EYE PIGMENTATION 5, BLACK/NONBLACK HAIR

              SKIN/HAIR/EYE PIGMENTATION 5, DARK/FAIR SKIN, INCLUDED
           SKIN/HAIR/EYE PIGMENTATION 5, DARK/LIGHT EYES, INCLUDED

                   HYPERTENSION, DIASTOLIC, RESISTANCE TO

                        GMP REDUCTASE POLYMORPHISM

                          AUTISM, SUSCEPTIBILITY TO

                     ASTHMA AND ATOPY, SUSCEPTIBILITY TO

                           ASTHMA SUSCEPTIBILITY 2

            CORONARY ARTERY DISEASE, SUSCEPTIBILITY TO, INCLUDED

             CORONARY ARTERY SPASM, SUSCEPTIBILITY TO, INCLUDED

                      PON1 ENZYME ACTIVITY, VARIATION IN

                             CFTR POLYMORPHISM

                        PHENYLTHIOCARBAMIDE TASTING

                        PHENYLTHIOCARBAMIDE TASTING

                        PHENYLTHIOCARBAMIDE TASTING

                              ACETYLATION, SLOW

       HYPERCHOLESTEROLEMIA, FAMILIAL, DUE TO LDLR DEFECT, MODIFIER OF

              AUTOIMMUNE THYROID DISEASE, SUSCEPTIBILITY TO, 3

CORONARY HEART DISEASE IN FAMILIAL HYPERCHOLESTEROLEMIA, PROTECTION AGAINST

         AMINOLEVULINATE DEHYDRATASE, ALAD*1/ALAD*2 POLYMORPHISM

                          PREECLAMPSIA/ECLAMPSIA 4

         DIABETES MELLITUS, NONINSULIN-DEPENDENT, SUSCEPTIBILITY TO

               ANOREXIA NERVOSA, SUSCEPTIBILITY TO, 2, INCLUDED

           BIPOLAR AFFECTIVE DISORDER, SUSCEPTIBILITY TO, INCLUDED

                BULIMIA NERVOSA, SUSCEPTIBILITY TO, 2, INCLUDED

                    MEMORY IMPAIRMENT, SUSCEPTIBILITY TO

        OBSESSIVE-COMPULSIVE DISORDER, PROTECTION AGAINST, INCLUDED

         PARKINSON DISEASE, AGE AT ONSET, SUSCEPTIBILITY TO, INCLUDED

                           COLON CANCER, SOMATIC

               SKIN/HAIR/EYE PIGMENTATION 10, BLOND/BROWN HAIR

              DOPAMINE RECEPTOR D2, REDUCED BRAIN DENSITY OF
      DOPAMINE RECEPTOR D2, REDUCED BRAIN DENSITY OF

         DIABETES MELLITUS, TYPE 1, SUSCEPTIBILITY TO

           CEREBRAL INFARCTION, SUSCEPTIBILITY TO

                  ATOPY, SUSCEPTIBILITY TO

                      EAR WAX, WET/DRY

PLATELET-ENDOTHELIAL CELL ADHESION MOLECULE 1 POLYMORPHISM

             INOSINE TRIPHOSPHATASE DEFICIENCY

              COLON CANCER, SUSCEPTIBILITY TO

             HEPATITIS B VIRUS, SUSCEPTIBILITY TO

                     TCN2 POLYMORPHISM

       PYRUVATE DEHYDROGENASE E1-ALPHA DEFICIENCY
Coordinates               Genotype
Gene, amino acid change   Trait-associated allele
chr1:25589952             C/G
RHCE, P226A               C
chr1:46643348             C/A
FAAH, P129T               A
chr1:65809029             A/G
LEPR, K109R               G
chr1:65831101             G/G
LEPR, Q223R               G
chr1:194908856            G/A
CFH, I62V                 G
chr1:201460809            C/T
CHIT1, G102S              T
chr1:224086256            C/C
EPHX1, Y113H              C
chr1:224086256            C/C
EPHX1, Y113H              C
chr1:224086256            C/C
EPHX1, Y113H              C
chr1:224086256            C/C
EPHX1, Y113H              C
chr2:49043425             C/T
FSHR, N680S               C
chr2:49043425             C/T
FSHR, N680S               C
chr2:49044545             C/T
FSHR, T307A               C
chr2:108880033            G/G
EDAR, V370A               G
chr2:218967976            G/A
SLC11A1, D543N            A
chr2:230758959            G/G
SP110, L425S              G
chr4:2876505              G/T
ADD1, G460W               T
chr5:35896825             T/C
IL7R, T66I                T
chr5:35896825             T/C
IL7R, T66I                T
chr5:35906947             G/A
IL7R, I138V               G
chr5:35906947             G/A
IL7R, I138V               G
chr5:74020971             A/G
HEXB, K121R               G
chr5:131741971            G/A
SLC22A5, W132*            A
chr6:16398740             A/A
GMPR, F256I               A
chr6:32011783             G/C
C2, E318D                 C
chr6:32904663             A/G
TAP2, Q687*               A
chr6:36759949             C/A
CDKN1A, S31R              A
chr7:34784638     T/T
NPSR1, N107I      T
chr7:94872711     G/C
PON2, C311S       G
chr7:94878952     G/C
PON2, A148G       C
chr7:138068331    G/G
ATP6V0A4, M580T   G
chr7:141319073    T/C
TAS2R38, I296V    C
chr7:141319174    G/A
TAS2R38, V262A    G
chr7:141319814    C/G
TAS2R38, A49P     G
chr8:27429782     G/A
EPHX2, R287Q      A
chr8:55701948     A/T
RP1, N985Y        T
chr8:91059697     T/C
NBN, I171V        C
chr8:91059697     T/C
NBN, I171V        C
chr8:133969434    G/G
TG, S734A         G
chr10:13192406    T/A
OPTN, M98K        A
chr10:13192406    T/A
OPTN, M98K        A
chr10:70311866    C/C
STOX1, Y153H      C
chr10:96530400    G/A
CYP2C19, W212*    A
chr10:96530400    G/A
CYP2C19, W212*    A
chr11:48101951    C/C
PTPRJ, Q276P      C
chr11:112776038   G/A
ANKK1, E713K      A
chr12:14884706    C/T
ART4, N265D       C
chr12:110726149   A/A
ALDH2, E504K      A
chr12:110726149   A/A
ALDH2, E504K      A
chr12:110726149   A/A
ALDH2, E504K      A
chr12:120779718   T/C
HPD, A33T         T
chr14:20010446    G/A
NP, S51G          G
chr14:63978598    G/A
MTHFD1, R653Q     A
chr14:63978598    G/A
MTHFD1, R653Q     A
chr16:3647748     G/A
DNASE1, Q244R     G
chr16:46815699    T/T
ABCC11, G180R    T
chr16:68302646   G/A
NQO1, P187S      A
chr16:68302646   G/A
NQO1, P187S      A
chr16:68302646   G/A
NQO1, P187S      A
chr17:7520197    C/C
TP53, P72R       C
chr17:19753133   T/C
AKAP10, I646V    C
chr17:59804699   G/C
PECAM1, L125V    C
chr20:4628251    A/G
PRNP, M129V      G
chr20:4628251    A/G
PRNP, M129V      G
chr20:4628251    A/G
PRNP, M129V      G
chr20:54394948   T/T
AURKA, F31I      T
chr21:33536120   T/C
IFNAR2, S8F      T
chr22:49411282   C/C
ARSA, N350S      C
chrX:19285703    A/C
PDHA1, M282L     C
chrX:113871991   G/C
HTR2C, C23S      C
                            Associated trait

                        RH E/e POLYMORPHISM

                  DRUG ADDICTION, SUSCEPTIBILITY TO

                   LEPTIN RECEPTOR POLYMORPHISM

                   LEPTIN RECEPTOR POLYMORPHISM

       MACULAR DEGENERATION, AGE-RELATED, 4, SUSCEPTIBILITY TO

                     CHITOTRIOSIDASE DEFICIENCY

               EMPHYSEMA, SUSCEPTIBILITY TO, INCLUDED

          LYMPHOPROLIFERATIVE DISORDERS, SUSCEPTIBILITY TO

              PREECLAMPSIA, SUSCEPTIBILITY TO, INCLUDED

PULMONARY DISEASE, CHRONIC OBSTRUCTIVE, SUSCEPTIBILITY TO, INCLUDED

OVARIAN HYPERSTIMULATION SYNDROME, MODIFIER OF SEVERITY OF, INCLUDED

                OVARIAN RESPONSE TO FSH STIMULATION

                OVARIAN RESPONSE TO FSH STIMULATION

                 HAIR MORPHOLOGY 1, HAIR THICKNESS

                   BURULI ULCER, SUSCEPTIBILITY TO

           MYCOBACTERIUM TUBERCULOSIS, SUSCEPTIBILITY TO

      HYPERTENSION, SALT-SENSITIVE ESSENTIAL, SUSCEPTIBILITY TO

                   B CELL-POSITIVE, NK CELL-POSITIVE

  SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-
                           NEGATIVE,

                   B CELL-POSITIVE, NK CELL-POSITIVE

  SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-
                           NEGATIVE,

                         HEXB POLYMORPHISM

               CARNITINE DEFICIENCY, SYSTEMIC PRIMARY

                   GMP REDUCTASE POLYMORPHISM

        MACULAR DEGENERATION, AGE-RELATED, REDUCED RISK OF

              PEPTIDE TRANSPORTER PSF2 POLYMORPHISM

            CIP1/WAF1 TUMOR-ASSOCIATED POLYMORPHISM 1
                       ASTHMA SUSCEPTIBILITY 2

                    PARAOXONASE 2 POLYMORPHISM

                    PARAOXONASE 2 POLYMORPHISM

         RENAL TUBULAR ACIDOSIS, DISTAL, AUTOSOMAL RECESSIVE

                    PHENYLTHIOCARBAMIDE TASTING

                    PHENYLTHIOCARBAMIDE TASTING

                    PHENYLTHIOCARBAMIDE TASTING

   HYPERCHOLESTEROLEMIA, FAMILIAL, DUE TO LDLR DEFECT, MODIFIER OF

               HYPERTRIGLYCERIDEMIA, SUSCEPTIBILITY TO

                           APLASTIC ANEMIA

      LYMPHOBLASTIC LEUKEMIA, ACUTE, SUSCEPTIBILITY TO, INCLUDED

           AUTOIMMUNE THYROID DISEASE, SUSCEPTIBILITY TO, 3

                 GLAUCOMA 1, OPEN ANGLE, E, INCLUDED

             GLAUCOMA, NORMAL TENSION, SUSCEPTIBILITY TO

                      PREECLAMPSIA/ECLAMPSIA 4

                  MEPHENYTOIN, POOR METABOLISM OF

               PROGUANIL, POOR METABOLISM OF, INCLUDED

                       COLON CANCER, SOMATIC

           DOPAMINE RECEPTOR D2, REDUCED BRAIN DENSITY OF

                       DOMBROCK BLOOD GROUP

                      ALCOHOL SENSITIVITY, ACUTE

                HANGOVER, SUSCEPTIBILITY TO, INCLUDED

SUBLINGUAL NITROGLYCERIN, SUSCEPTIBILITY TO POOR RESPONSE TO, INCLUDED

                            HAWKINSINURIA

              NUCLEOSIDE PHOSPHORYLASE POLYMORPHISM

           ABRUPTIO PLACENTAE, SUSCEPTIBILITY TO, INCLUDED

       NEURAL TUBE DEFECTS, FOLATE-SENSITIVE, SUSCEPTIBILITY TO

           SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO

                          EAR WAX, WET/DRY
                     EAR WAX, WET/DRY

             BENZENE TOXICITY, SUSCEPTIBILITY TO

BREAST CANCER, POST-CHEMOTHERAPY POOR SURVIVAL IN, INCLUDED

  LEUKEMIA, POST-CHEMOTHERAPY, SUSCEPTIBILITY TO, INCLUDED

                  CODON 72 POLYMORPHISM

        CARDIAC CONDUCTION DEFECT, SUSCEPTIBILITY TO

PLATELET-ENDOTHELIAL CELL ADHESION MOLECULE 1 POLYMORPHISM

 ALZHEIMER DISEASE, EARLY-ONSET, SUSCEPTIBILITY TO, INCLUDED

  APHASIA, PRIMARY PROGRESSIVE, SUSCEPTIBILITY TO, INCLUDED

              PRION DISEASE, SUSCEPTIBILITY TO

              COLON CANCER, SUSCEPTIBILITY TO

             HEPATITIS B VIRUS, SUSCEPTIBILITY TO

               ARYLSULFATASE A POLYMORPHISM

       PYRUVATE DEHYDROGENASE E1-ALPHA DEFICIENCY

         SEROTONIN 5-HT-2C RECEPTOR POLYMORPHISM
Coordinates               Genotype
Gene, amino acid change   Trait-associated allele
chr1:9246497              G/A
H6PD, R453Q               A
chr1:65809029             G/G
LEPR, K109R               G
chr1:65831101             G/G
LEPR, Q223R               G
chr1:152693594            C/C
IL6R, D358A               C
chr1:167963570            G/A
SELE, H468Y               A
chr1:180821180            C/T
RNASEL, R462Q             T
chr1:194908856            G/A
CFH, I62V                 G
chr1:221351823            G/A
TLR5, R392*               A
chr1:221351823            G/A
TLR5, R392*               A
chr1:224086256            C/C
EPHX1, Y113H              C
chr1:224086256            C/C
EPHX1, Y113H              C
chr1:224086256            C/C
EPHX1, Y113H              C
chr1:224086256            C/C
EPHX1, Y113H              C
chr2:108880033            G/G
EDAR, V370A               G
chr2:218967976            G/A
SLC11A1, D543N            A
chr2:230758959            G/G
SP110, L425S              G
chr2:233848107            A/G
ATG16L1, T300A            G
chr3:46374212             G/A
CCR2, V64I                A
chr3:46390065             G/A
CCR5, R223Q               A
chr4:2876505              T/T
ADD1, G460W               T
chr4:38475043             C/A
TLR1, I602S               C
chr4:100458342            T/C
ADH1B, R48H               T
chr4:100458342            T/C
ADH1B, R48H               T
chr4:100479812            T/C
ADH1C, I350V              C
chr4:100482988            C/T
ADH1C, R272Q              T
chr5:7923973              G/G
MTRR, I22M                G
chr5:7923973              G/G
MTRR, I22M                G
chr5:33999627             T/T
SLC45A2, E272K            T
chr5:33999627             T/T
SLC45A2, E272K    T
chr5:33999627     T/T
SLC45A2, E272K    T
chr5:74020971     A/G
HEXB, K121R       G
chr5:121441107    C/T
LOX, R158Q        T
chr6:12404241     G/T
EDN1, K198N       T
chr6:12404241     G/T
EDN1, K198N       T
chr6:16398740     A/A
GMPR, F256I       A
chr6:32022159     G/A
CFB, R32Q         A
chr6:36759949     C/A
CDKN1A, S31R      A
chr7:34784638     T/T
NPSR1, N107I      T
chr7:80123939     C/T
CD36, P90S        T
chr7:141319073    T/C
TAS2R38, I296V    C
chr7:141319174    G/A
TAS2R38, V262A    G
chr7:141319814    C/G
TAS2R38, A49P     G
chr8:18302383     G/A
NAT2, R197Q       A
chr8:118253964    C/T
SLC30A8, R325W    T
chr8:133969434    G/G
TG, S734A         G
chr10:54201241    T/T
MBL2, G54D        T
chr10:54201241    T/T
MBL2, G54D        T
chr10:70311866    C/C
STOX1, Y153H      C
chr10:101819504   C/T
CPN1, G178D       T
chr11:17366148    T/C
KCNJ11, E23K      T
chr11:27636492    C/T
BDNF, V66M        T
chr11:27636492    C/T
BDNF, V66M        T
chr11:27636492    C/T
BDNF, V66M        T
chr11:27636492    C/T
BDNF, V66M        T
chr11:27636492    C/T
BDNF, V66M        T
chr11:27636492    C/T
BDNF, V66M        T
chr11:59619680    A/G
MS4A2, E237G      G
chr12:120779718   T/C
HPD, A33T         T
chr13:31804729    A/C
BRCA2, N372H      C
chr14:60993992   G/A
PRKCH, V374I     A
chr15:46213776   A/G
SLC24A5, A111T   A
chr15:72006599   G/T
LOXL1, R141L     T
chr15:72006635   G/A
LOXL1, G153D     A
chr16:3647748    G/A
DNASE1, Q244R    G
chr16:27281681   T/C
IL4R, S503P      C
chr16:27281681   T/C
IL4R, S503P      C
chr16:27281901   A/G
IL4R, Q576R      G
chr16:46815699   T/T
ABCC11, G180R    T
chr17:7520197    G/C
TP53, P72R       C
chr17:19753133   T/C
AKAP10, I646V    C
chr17:35133114   A/G
ERBB2, V655I     A
chr17:45792455   C/G
XYLT2, T801R     G
chr20:54394948   A/T
AURKA, F31I      T
chr21:33562658   A/G
IL10RB, E47K     A
chrX:31406347    C
DMD, N2912D      C
chrX:31406352    A
DMD, E2910V      A
                        Associated trait


              CORTISONE REDUCTASE DEFICIENCY

               LEPTIN RECEPTOR POLYMORPHISM

               LEPTIN RECEPTOR POLYMORPHISM

       INTERLEUKIN-6 SOLUBLE RECEPTOR, SERUM LEVEL OF

             IgA NEPHROPATHY, SUSCEPTIBILITY TO

             PROSTATE CANCER, SUSCEPTIBILITY TO

   MACULAR DEGENERATION, AGE-RELATED, 4, SUSCEPTIBILITY TO

            LEGIONNAIRE DISEASE, SUSCEPTIBILITY TO

  SYSTEMIC LUPUS ERYTHEMATOSUS, RESISTANCE TO, 1, INCLUDED

           EMPHYSEMA, SUSCEPTIBILITY TO, INCLUDED

      LYMPHOPROLIFERATIVE DISORDERS, SUSCEPTIBILITY TO

          PREECLAMPSIA, SUSCEPTIBILITY TO, INCLUDED

 PULMONARY DISEASE, CHRONIC OBSTRUCTIVE, SUSCEPTIBILITY TO,
                        INCLUDED

             HAIR MORPHOLOGY 1, HAIR THICKNESS

               BURULI ULCER, SUSCEPTIBILITY TO

       MYCOBACTERIUM TUBERCULOSIS, SUSCEPTIBILITY TO

      INFLAMMATORY BOWEL DISEASE 10, SUSCEPTIBILITY TO

     HUMAN IMMUNODEFICIENCY VIRUS TYPE 1, RESISTANCE TO

               CCR5 POLYMORPHISM, ORIENTAL 2

  HYPERTENSION, SALT-SENSITIVE ESSENTIAL, SUSCEPTIBILITY TO

                LEPROSY, PROTECTION AGAINST

AERODIGESTIVE TRACT CANCER, SQUAMOUS CELL, ALCOHOL-RELATED,
                PROTECTION AGAINST; INCLUDED

          ALCOHOL DEPENDENCE, PROTECTION AGAINST

          ALCOHOL DEPENDENCE, PROTECTION AGAINST

          ALCOHOL DEPENDENCE, PROTECTION AGAINST

         DOWN SYNDROME, SUSCEPTIBILITY TO, INCLUDED

   NEURAL TUBE DEFECTS, FOLATE-SENSITIVE, SUSCEPTIBILITY TO

      SKIN/HAIR/EYE PIGMENTATION 5, BLACK/NONBLACK HAIR

    SKIN/HAIR/EYE PIGMENTATION 5, DARK/FAIR SKIN, INCLUDED
     SKIN/HAIR/EYE PIGMENTATION 5, DARK/FAIR SKIN, INCLUDED

    SKIN/HAIR/EYE PIGMENTATION 5, DARK/LIGHT EYES, INCLUDED

                      HEXB POLYMORPHISM

                 LYSYL OXIDASE POLYMORPHISM

                               7

HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT
                            LOCUS

                GMP REDUCTASE POLYMORPHISM

    MACULAR DEGENERATION, AGE-RELATED, REDUCED RISK OF

         CIP1/WAF1 TUMOR-ASSOCIATED POLYMORPHISM 1

                    ASTHMA SUSCEPTIBILITY 2

             PLATELET GLYCOPROTEIN IV DEFICIENCY

                PHENYLTHIOCARBAMIDE TASTING

                PHENYLTHIOCARBAMIDE TASTING

                PHENYLTHIOCARBAMIDE TASTING

                      ACETYLATION, SLOW

  DIABETES MELLITUS, NONINSULIN-DEPENDENT, SUSCEPTIBILITY TO

       AUTOIMMUNE THYROID DISEASE, SUSCEPTIBILITY TO, 3

  GESTATIONAL DIABETES MELLITUS, SUSCEPTIBILITY TO, INCLUDED

             MANNOSE-BINDING PROTEIN DEFICIENCY

                  PREECLAMPSIA/ECLAMPSIA 4

                CARBOXYPEPTIDASE N DEFICIENCY

  DIABETES MELLITUS, NONINSULIN-DEPENDENT, SUSCEPTIBILITY TO

       ANOREXIA NERVOSA, SUSCEPTIBILITY TO, 2, INCLUDED

   BIPOLAR AFFECTIVE DISORDER, SUSCEPTIBILITY TO, INCLUDED

        BULIMIA NERVOSA, SUSCEPTIBILITY TO, 2, INCLUDED

            MEMORY IMPAIRMENT, SUSCEPTIBILITY TO

OBSESSIVE-COMPULSIVE DISORDER, PROTECTION AGAINST, INCLUDED

 PARKINSON DISEASE, AGE AT ONSET, SUSCEPTIBILITY TO, INCLUDED

               ATOPIC ASTHMA, SUSCEPTIBILITY TO

                        HAWKINSINURIA

     BREAST-OVARIAN CANCER, FAMILIAL, SUSCEPTIBILITY TO, 2
      CEREBRAL INFARCTION, SUSCEPTIBILITY TO

    SKIN/HAIR/EYE PIGMENTATION 4, FAIR/DARK SKIN

     EXFOLIATION SYNDROME, SUSCEPTIBILITY TO

     EXFOLIATION SYNDROME, SUSCEPTIBILITY TO

 SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO

             ASTHMA, SUSCEPTIBILITY TO

               ATOPY, RESISTANCE TO

             ATOPY, SUSCEPTIBILITY TO

                 EAR WAX, WET/DRY

             CODON 72 POLYMORPHISM

   CARDIAC CONDUCTION DEFECT, SUSCEPTIBILITY TO

               ERBB2 POLYMORPHISM

PSEUDOXANTHOMA ELASTICUM, MODIFIER OF SEVERITY OF

         COLON CANCER, SUSCEPTIBILITY TO

        HEPATITIS B VIRUS, SUSCEPTIBILITY TO

         DUCHENNE MUSCULAR DYSTROPHY

         DUCHENNE MUSCULAR DYSTROPHY
Coordinates               Genotype
Gene, amino acid change   Trait-associated allele
chr1:9246497              G/A
H6PD, R453Q               A
chr1:65809029             A/G
LEPR, K109R               G
chr1:65831101             G/G
LEPR, Q223R               G
chr1:201460809            C/T
CHIT1, G102S              T
chr1:221351222            T/C
TLR5, N592S               C
chr1:224093029            A/G
EPHX1, H139R              G
chr2:49043425             C/T
FSHR, N680S               C
chr2:49043425             C/T
FSHR, N680S               C
chr2:49044545             C/T
FSHR, T307A               C
chr2:230758959            G/G
SP110, L425S              G
chr2:234333883            G/A
UGT1A1, G71R              A
chr2:234333883            G/A
UGT1A1, G71R              A
chr3:10306457             G/T
GHRL, L72M                T
chr3:10306457             G/T
GHRL, L72M                T
chr3:46374212             G/A
CCR2, V64I                A
chr4:2876505              G/T
ADD1, G460W               T
chr5:33999627             T/T
SLC45A2, E272K            T
chr5:33999627             T/T
SLC45A2, E272K            T
chr5:33999627             T/T
SLC45A2, E272K            T
chr5:35896825             T/C
IL7R, T66I                T
chr5:35896825             T/C
IL7R, T66I                T
chr5:35906947             G/A
IL7R, I138V               G
chr5:35906947             G/A
IL7R, I138V               G
chr5:121441107            C/T
LOX, R158Q                T
chr5:147461148            A/G
SPINK5, E420K             A
chr5:147461148            A/G
SPINK5, E420K             A
chr5:147461148            A/G
SPINK5, E420K     A
chr5:148186633    G/A
ADRB2, R16G       G
chr5:148186633    G/A
ADRB2, R16G       G
chr5:148186666    G/C
ADRB2, Q27E       G
chr5:148186666    G/C
ADRB2, Q27E       G
chr5:148186666    G/C
ADRB2, Q27E       G
chr6:16398740     A/A
GMPR, F256I       A
chr6:32908390     C/T
TAP2, I379V       C
chr6:36759949     A/A
CDKN1A, S31R      A
chr6:149763383    G/A
SUMO4, M55V       G
chr6:160033862    A/G
SOD2, A16V        A
chr6:160033862    A/G
SOD2, A16V        A
chr7:94775382     C/C
PON1, Q192R       C
chr7:94775382     C/C
PON1, Q192R       C
chr7:94775382     C/C
PON1, Q192R       C
chr8:18302650     G/A
NAT2, G286E       A
chr8:27429782     G/A
EPHX2, R287Q      A
chr8:118253964    T/T
SLC30A8, R325W    T
chr8:133969434    G/G
TG, S734A         G
chr10:54201241    C/T
MBL2, G54D        T
chr10:54201241    C/T
MBL2, G54D        T
chr10:70311866    C/C
STOX1, Y153H      C
chr10:75343107    T/C
PLAU, P141L       T
chr10:101568567   C/T
ABCC2, R768W      T
chr10:115795046   G/C
ADRB1, R389G      G
chr11:27636492    T/T
BDNF, V66M        T
chr11:27636492    T/T
BDNF, V66M        T
chr11:27636492    T/T
BDNF, V66M        T
chr11:27636492    T/T
BDNF, V66M        T
chr11:27636492    T/T
BDNF, V66M        T
chr11:27636492    T/T
BDNF, V66M        T
chr11:116166602   C/A
APOA5, G185C      A
chr12:111833253   G/A
OAS1, S162G       G
chr14:60993992    G/A
PRKCH, V374I      A
chr14:63978598    G/A
MTHFD1, R653Q     A
chr14:63978598    G/A
MTHFD1, R653Q     A
chr15:25902148    C/T
OCA2, A481T       T
chr15:48665922    A/A
TRPM7, T1482I     A
chr15:63281265    A/G
CILP, I395T       G
chr15:72006635    G/A
LOXL1, G153D      A
chr16:46815699    T/T
ABCC11, G180R     T
chr16:68302646    G/A
NQO1, P187S       A
chr16:68302646    G/A
NQO1, P187S       A
chr16:68302646    G/A
NQO1, P187S       A
chr17:45792455    C/G
XYLT2, T801R      G
chr18:9107867     T/C
NDUFV2, A29V      T
chr20:4628521     G/A
PRNP, E219K       A
chr20:54394948    A/T
AURKA, F31I       T
chr22:18331271    A/A
COMT, V158M       A
chr22:40856638    G/A
CYP2D6, P34S      A
                          Associated trait


               CORTISONE REDUCTASE DEFICIENCY

                LEPTIN RECEPTOR POLYMORPHISM

                LEPTIN RECEPTOR POLYMORPHISM

                  CHITOTRIOSIDASE DEFICIENCY

             LEGIONNAIRE DISEASE, SUSCEPTIBILITY TO

               EPOXIDE HYDROLASE POLYMORPHISM

 OVARIAN HYPERSTIMULATION SYNDROME, MODIFIER OF SEVERITY OF,
                         INCLUDED

             OVARIAN RESPONSE TO FSH STIMULATION

             OVARIAN RESPONSE TO FSH STIMULATION

        MYCOBACTERIUM TUBERCULOSIS, SUSCEPTIBILITY TO

                       GILBERT SYNDROME

   HYPERBILIRUBINEMIA, TRANSIENT FAMILIAL NEONATAL, INCLUDED

        METABOLIC SYNDROME, SUSCEPTIBILITY TO, INCLUDED

                    OBESITY, AGE AT ONSET OF

      HUMAN IMMUNODEFICIENCY VIRUS TYPE 1, RESISTANCE TO

   HYPERTENSION, SALT-SENSITIVE ESSENTIAL, SUSCEPTIBILITY TO

       SKIN/HAIR/EYE PIGMENTATION 5, BLACK/NONBLACK HAIR

     SKIN/HAIR/EYE PIGMENTATION 5, DARK/FAIR SKIN, INCLUDED

     SKIN/HAIR/EYE PIGMENTATION 5, DARK/LIGHT EYES, INCLUDED

                B CELL-POSITIVE, NK CELL-POSITIVE

SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-
                         NEGATIVE,

                B CELL-POSITIVE, NK CELL-POSITIVE

SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-
                         NEGATIVE,

                  LYSYL OXIDASE POLYMORPHISM

              ASTHMA, SUSCEPTIBILITY TO, INCLUDED

                    ATOPY, SUSCEPTIBILITY TO

        DERMATITIS, ATOPIC, 6, SUSCEPTIBILITY TO, INCLUDED
        DERMATITIS, ATOPIC, 6, SUSCEPTIBILITY TO, INCLUDED

              ASTHMA, NOCTURNAL, SUSCEPTIBILITY TO

        METABOLIC SYNDROME, SUSCEPTIBILITY TO, INCLUDED

         ASTHMA, CHILDHOOD, SUSCEPTIBILITY TO, INCLUDED

        METABOLIC SYNDROME, SUSCEPTIBILITY TO, INCLUDED

                   OBESITY, SUSCEPTIBILITY TO

                 GMP REDUCTASE POLYMORPHISM

            PEPTIDE TRANSPORTER PSF2 POLYMORPHISM

          CIP1/WAF1 TUMOR-ASSOCIATED POLYMORPHISM 1

             DIABETES MELLITUS, INSULIN-DEPENDENT, 5

 MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 6,
                         INCLUDED

             SUPEROXIDE DISMUTASE 2 POLYMORPHISM

      CORONARY ARTERY DISEASE, SUSCEPTIBILITY TO, INCLUDED

      CORONARY ARTERY SPASM, SUSCEPTIBILITY TO, INCLUDED

               PON1 ENZYME ACTIVITY, VARIATION IN

                       ACETYLATION, SLOW

HYPERCHOLESTEROLEMIA, FAMILIAL, DUE TO LDLR DEFECT, MODIFIER OF

   DIABETES MELLITUS, NONINSULIN-DEPENDENT, SUSCEPTIBILITY TO

        AUTOIMMUNE THYROID DISEASE, SUSCEPTIBILITY TO, 3

   GESTATIONAL DIABETES MELLITUS, SUSCEPTIBILITY TO, INCLUDED

              MANNOSE-BINDING PROTEIN DEFICIENCY

                   PREECLAMPSIA/ECLAMPSIA 4

        ALZHEIMER DISEASE, LATE-ONSET, SUSCEPTIBILITY TO

                    DUBIN-JOHNSON SYNDROME

CONGESTIVE HEART FAILURE AND BETA-BLOCKER RESPONSE, MODIFIER OF

        ANOREXIA NERVOSA, SUSCEPTIBILITY TO, 2, INCLUDED

     BIPOLAR AFFECTIVE DISORDER, SUSCEPTIBILITY TO, INCLUDED

         BULIMIA NERVOSA, SUSCEPTIBILITY TO, 2, INCLUDED

              MEMORY IMPAIRMENT, SUSCEPTIBILITY TO
 OBSESSIVE-COMPULSIVE DISORDER, PROTECTION AGAINST, INCLUDED

  PARKINSON DISEASE, AGE AT ONSET, SUSCEPTIBILITY TO, INCLUDED

            HYPERTRIGLYCERIDEMIA, SUSCEPTIBILITY TO

           DIABETES MELLITUS, TYPE 1, SUSCEPTIBILITY TO

             CEREBRAL INFARCTION, SUSCEPTIBILITY TO

        ABRUPTIO PLACENTAE, SUSCEPTIBILITY TO, INCLUDED

    NEURAL TUBE DEFECTS, FOLATE-SENSITIVE, SUSCEPTIBILITY TO

               ALBINISM, OCULOCUTANEOUS, TYPE II

AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,
                      SUSCEPTIBILITY TO

             LUMBAR DISC DISEASE, SUSCEPTIBILITY TO

            EXFOLIATION SYNDROME, SUSCEPTIBILITY TO

                        EAR WAX, WET/DRY

               BENZENE TOXICITY, SUSCEPTIBILITY TO

 BREAST CANCER, POST-CHEMOTHERAPY POOR SURVIVAL IN, INCLUDED

   LEUKEMIA, POST-CHEMOTHERAPY, SUSCEPTIBILITY TO, INCLUDED

      PSEUDOXANTHOMA ELASTICUM, MODIFIER OF SEVERITY OF

              PARKINSON DISEASE, SUSCEPTIBILITY TO

        CREUTZFELDT-JAKOB DISEASE, PROTECTION AGAINST

                COLON CANCER, SUSCEPTIBILITY TO

         CATECHOL-O-METHYLTRANSFERASE POLYMORPHISM

               DEBRISOQUINE, POOR METABOLISM OF
Coordinates               Genotype
Gene, amino acid change   Trait-associated allele
chr1:9246497              G/A
H6PD, R453Q               A
chr1:65809029             G/G
LEPR, K109R               G
chr1:65831101             G/G
LEPR, Q223R               G
chr1:169346704            G/A
FMO3, V257M               A
chr1:194908856            G/A
CFH, I62V                 G
chr1:205173101            G/A
PIGR, A580V               A
chr1:221351222            T/C
TLR5, N592S               C
chr1:224086256            C/C
EPHX1, Y113H              C
chr1:224086256            C/C
EPHX1, Y113H              C
chr1:224086256            C/C
EPHX1, Y113H              C
chr1:224086256            C/C
EPHX1, Y113H              C
chr2:108880033            A/G
EDAR, V370A               G
chr2:230758959            G/G
SP110, L425S              G
chr4:2876505              T/T
ADD1, G460W               T
chr4:102970099            G/A
BANK1, R61H               A
chr5:35896825             T/C
IL7R, T66I                T
chr5:35896825             T/C
IL7R, T66I                T
chr5:35906947             G/A
IL7R, I138V               G
chr5:35906947             G/A
IL7R, I138V               G
chr5:74020971             A/G
HEXB, K121R               G
chr5:121441107            C/T
LOX, R158Q                T
chr5:147461148            A/G
SPINK5, E420K             A
chr5:147461148            A/G
SPINK5, E420K             A
chr5:147461148            A/G
SPINK5, E420K             A
chr5:148186633            G/A
ADRB2, R16G               G
chr5:148186633            G/A
ADRB2, R16G               G
chr5:148186666            G/C
ADRB2, Q27E               G
chr5:148186666    G/C
ADRB2, Q27E       G
chr5:148186666    G/C
ADRB2, Q27E       G
chr6:12404241     G/T
EDN1, K198N       T
chr6:12404241     G/T
EDN1, K198N       T
chr6:16398740     A/A
GMPR, F256I       A
chr7:34784638     A/T
NPSR1, N107I      T
chr7:94775382     C/C
PON1, Q192R       C
chr7:94775382     C/C
PON1, Q192R       C
chr7:94775382     C/C
PON1, Q192R       C
chr7:141319073    C/C
TAS2R38, I296V    C
chr7:141319814    G/G
TAS2R38, A49P     G
chr8:18302383     A/A
NAT2, R197Q       A
chr8:27429782     G/A
EPHX2, R287Q      A
chr8:133969434    G/G
TG, S734A         G
chr9:106660688    C/T
ABCA1, R219K      T
chr10:13192406    T/A
OPTN, M98K        A
chr10:13192406    T/A
OPTN, M98K        A
chr10:70311866    C/C
STOX1, Y153H      C
chr10:75343107    T/C
PLAU, P141L       T
chr10:115794026   A/G
ADRB1, S49G       G
chr11:27636492    C/T
BDNF, V66M        T
chr11:27636492    C/T
BDNF, V66M        T
chr11:27636492    C/T
BDNF, V66M        T
chr11:27636492    C/T
BDNF, V66M        T
chr11:27636492    C/T
BDNF, V66M        T
chr11:27636492    C/T
BDNF, V66M        T
chr11:48101951    C/C
PTPRJ, Q276P      C
chr12:120779718   T/C
HPD, A33T         T
chr14:60993992    G/A
PRKCH, V374I     A
chr15:72006599   G/T
LOXL1, R141L     T
chr16:27281901   A/G
IL4R, Q576R      G
chr16:46815699   C/T
ABCC11, G180R    T
chr16:68302646   G/A
NQO1, P187S      A
chr16:68302646   G/A
NQO1, P187S      A
chr16:68302646   G/A
NQO1, P187S      A
chr17:19753133   C/C
AKAP10, I646V    C
chr17:25600202   T/C
BLMH, I443V      C
chr17:35133114   A/G
ERBB2, V655I     A
chr18:9107867    T/C
NDUFV2, A29V     T
chr20:3141842    C/A
ITPA, P32T       A
chr20:54394948   A/T
AURKA, F31I      T
chr21:33562658   A/G
IL10RB, E47K     A
chr22:18330263   G/T
COMT, A72S       T
chr22:29341610   G/C
TCN2, P259R      G
chr22:40856638   G/A
CYP2D6, P34S     A
                       Associated trait

             CORTISONE REDUCTASE DEFICIENCY

             LEPTIN RECEPTOR POLYMORPHISM

             LEPTIN RECEPTOR POLYMORPHISM

                    TRIMETHYLAMINURIA

 MACULAR DEGENERATION, AGE-RELATED, 4, SUSCEPTIBILITY TO

            IgA NEPHROPATHY, SUSCEPTIBILITY TO

          LEGIONNAIRE DISEASE, SUSCEPTIBILITY TO

          EMPHYSEMA, SUSCEPTIBILITY TO, INCLUDED

    LYMPHOPROLIFERATIVE DISORDERS, SUSCEPTIBILITY TO

        PREECLAMPSIA, SUSCEPTIBILITY TO, INCLUDED

PULMONARY DISEASE, CHRONIC OBSTRUCTIVE, SUSCEPTIBILITY TO,
                       INCLUDED

            HAIR MORPHOLOGY 1, HAIR THICKNESS

     MYCOBACTERIUM TUBERCULOSIS, SUSCEPTIBILITY TO

 HYPERTENSION, SALT-SENSITIVE ESSENTIAL, SUSCEPTIBILITY TO

     SYSTEMIC LUPUS ERYTHMATOSUS, ASSOCIATION WITH

             B CELL-POSITIVE, NK CELL-POSITIVE

SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T
                     CELL-NEGATIVE,

             B CELL-POSITIVE, NK CELL-POSITIVE

SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T
                     CELL-NEGATIVE,

                   HEXB POLYMORPHISM

               LYSYL OXIDASE POLYMORPHISM

           ASTHMA, SUSCEPTIBILITY TO, INCLUDED

                 ATOPY, SUSCEPTIBILITY TO

     DERMATITIS, ATOPIC, 6, SUSCEPTIBILITY TO, INCLUDED

          ASTHMA, NOCTURNAL, SUSCEPTIBILITY TO

     METABOLIC SYNDROME, SUSCEPTIBILITY TO, INCLUDED

      ASTHMA, CHILDHOOD, SUSCEPTIBILITY TO, INCLUDED
      METABOLIC SYNDROME, SUSCEPTIBILITY TO, INCLUDED

                 OBESITY, SUSCEPTIBILITY TO

                              7

  HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE
                        TRAIT LOCUS

               GMP REDUCTASE POLYMORPHISM

                  ASTHMA SUSCEPTIBILITY 2

    CORONARY ARTERY DISEASE, SUSCEPTIBILITY TO, INCLUDED

    CORONARY ARTERY SPASM, SUSCEPTIBILITY TO, INCLUDED

             PON1 ENZYME ACTIVITY, VARIATION IN

               PHENYLTHIOCARBAMIDE TASTING

               PHENYLTHIOCARBAMIDE TASTING

                     ACETYLATION, SLOW

HYPERCHOLESTEROLEMIA, FAMILIAL, DUE TO LDLR DEFECT, MODIFIER
                           OF

      AUTOIMMUNE THYROID DISEASE, SUSCEPTIBILITY TO, 3

 CORONARY HEART DISEASE IN FAMILIAL HYPERCHOLESTEROLEMIA,
                   PROTECTION AGAINST

            GLAUCOMA 1, OPEN ANGLE, E, INCLUDED

        GLAUCOMA, NORMAL TENSION, SUSCEPTIBILITY TO

                 PREECLAMPSIA/ECLAMPSIA 4

      ALZHEIMER DISEASE, LATE-ONSET, SUSCEPTIBILITY TO

                    RESTING HEART RATE

      ANOREXIA NERVOSA, SUSCEPTIBILITY TO, 2, INCLUDED

   BIPOLAR AFFECTIVE DISORDER, SUSCEPTIBILITY TO, INCLUDED

       BULIMIA NERVOSA, SUSCEPTIBILITY TO, 2, INCLUDED

            MEMORY IMPAIRMENT, SUSCEPTIBILITY TO

OBSESSIVE-COMPULSIVE DISORDER, PROTECTION AGAINST, INCLUDED

PARKINSON DISEASE, AGE AT ONSET, SUSCEPTIBILITY TO, INCLUDED

                   COLON CANCER, SOMATIC

                       HAWKINSINURIA

           CEREBRAL INFARCTION, SUSCEPTIBILITY TO
         CEREBRAL INFARCTION, SUSCEPTIBILITY TO

        EXFOLIATION SYNDROME, SUSCEPTIBILITY TO

                ATOPY, SUSCEPTIBILITY TO

                   EAR WAX, WET/DRY

           BENZENE TOXICITY, SUSCEPTIBILITY TO

  BREAST CANCER, POST-CHEMOTHERAPY POOR SURVIVAL IN,
                       INCLUDED

LEUKEMIA, POST-CHEMOTHERAPY, SUSCEPTIBILITY TO, INCLUDED

     CARDIAC CONDUCTION DEFECT, SUSCEPTIBILITY TO

          BLEOMYCIN HYDROLASE POLYMORPHISM

                  ERBB2 POLYMORPHISM

          PARKINSON DISEASE, SUSCEPTIBILITY TO

           INOSINE TRIPHOSPHATASE DEFICIENCY

            COLON CANCER, SUSCEPTIBILITY TO

           HEPATITIS B VIRUS, SUSCEPTIBILITY TO

            SCHIZOPHRENIA, SUSCEPTIBILITY TO

                  TCN2 POLYMORPHISM

           DEBRISOQUINE, POOR METABOLISM OF
Coordinates               Genotype
Gene, amino acid change   Trait-associated allele
chr1:25589952             C/G
RHCE, P226A               C
chr1:46643348             C/A
FAAH, P129T               A
chr1:65809029             G/G
LEPR, K109R               G
chr1:65831101             G/G
LEPR, Q223R               G
chr1:194908856            G/A
CFH, I62V                 G
chr1:194925860            C/T
CFH, Y402H                C
chr1:194925860            C/T
CFH, Y402H                C
chr1:201460809            C/T
CHIT1, G102S              T
chr2:108880033            G/G
EDAR, V370A               G
chr2:138476119            C/T
HNMT, T105I               T
chr2:230758959            G/G
SP110, L425S              G
chr3:46374212             G/A
CCR2, V64I                A
chr3:123486447            G/T
CASR, A986S               T
chr5:7923973              A/G
MTRR, I22M                G
chr5:7923973              A/G
MTRR, I22M                G
chr5:33999627             C/T
SLC45A2, E272K            T
chr5:33999627             C/T
SLC45A2, E272K            T
chr5:33999627             C/T
SLC45A2, E272K            T
chr5:74020971             A/G
HEXB, K121R               G
chr5:147461148            A/G
SPINK5, E420K             A
chr5:147461148            A/G
SPINK5, E420K             A
chr5:147461148            A/G
SPINK5, E420K             A
chr6:12404241             T/T
EDN1, K198N               T
chr6:12404241             T/T
EDN1, K198N               T
chr6:16398740             T/A
GMPR, F256I               A
chr6:46780902             A/G
PLA2G7, A379V             A
chr7:34784638             A/T
NPSR1, N107I      T
chr7:94775382     T/C
PON1, Q192R       C
chr7:94775382     T/C
PON1, Q192R       C
chr7:94775382     T/C
PON1, Q192R       C
chr7:94784020     A/T
PON1, L55M        T
chr7:94784020     A/T
PON1, L55M        T
chr7:94784020     A/T
PON1, L55M        T
chr7:94872711     G/C
PON2, C311S       G
chr7:94878952     G/C
PON2, A148G       C
chr8:55701948     A/T
RP1, N985Y        T
chr8:118253964    T/T
SLC30A8, R325W    T
chr8:133969434    G/G
TG, S734A         G
chr9:106660688    C/T
ABCA1, R219K      T
chr10:70311866    C/C
STOX1, Y153H      C
chr10:75343107    T/C
PLAU, P141L       T
chr10:115795046   G/C
ADRB1, R389G      G
chr11:17366148    T/C
KCNJ11, E23K      T
chr11:27636492    C/T
BDNF, V66M        T
chr11:27636492    C/T
BDNF, V66M        T
chr11:27636492    C/T
BDNF, V66M        T
chr11:27636492    C/T
BDNF, V66M        T
chr11:27636492    C/T
BDNF, V66M        T
chr11:27636492    C/T
BDNF, V66M        T
chr11:59619680    A/G
MS4A2, E237G      G
chr11:68611939    G/A
TPCN2, G734E      A
chr12:9123535     T/C
A2M, V1000I       T
chr12:9123535     T/C
A2M, V1000I       T
chr12:111833253   G/A
OAS1, S162G       G
chr12:120779718   T/C
HPD, A33T         T
chr13:31804729   A/C
BRCA2, N372H     C
chr14:20010446   G/A
NP, S51G         G
chr14:60993992   G/A
PRKCH, V374I     A
chr14:63978598   G/A
MTHFD1, R653Q    A
chr14:63978598   G/A
MTHFD1, R653Q    A
chr15:63281265   A/G
CILP, I395T      G
chr15:72006599   G/T
LOXL1, R141L     T
chr16:3239469    C/T
MEFV, R408Q      T
chr16:3239587    A/A
MEFV, P369S      A
chr16:3647748    G/A
DNASE1, Q244R    G
chr16:27281901   A/G
IL4R, Q576R      G
chr16:46815699   T/T
ABCC11, G180R    T
chr16:68302646   A/A
NQO1, P187S      A
chr16:68302646   A/A
NQO1, P187S      A
chr16:68302646   A/A
NQO1, P187S      A
chr17:7520197    G/C
TP53, P72R       C
chr17:19753133   T/C
AKAP10, I646V    C
chr20:54394948   T/T
AURKA, F31I      T
chr21:33536120   T/C
IFNAR2, S8F      T
chr22:18330263   G/T
COMT, A72S       T
chr22:18331271   G/A
COMT, V158M      A
chr22:29341610   G/C
TCN2, P259R      G
chr22:40856638   A/A
CYP2D6, P34S     A
chr22:49411282   C/C
ARSA, N350S      C
chrX:31406347    C
DMD, N2912D      C
chrX:31406352    A
DMD, E2910V      A
                         Associated trait


                     RH E/e POLYMORPHISM

              DRUG ADDICTION, SUSCEPTIBILITY TO

               LEPTIN RECEPTOR POLYMORPHISM

               LEPTIN RECEPTOR POLYMORPHISM

   MACULAR DEGENERATION, AGE-RELATED, 4, SUSCEPTIBILITY TO

               BASAL LAMINAR DRUSEN, INCLUDED

   MACULAR DEGENERATION, AGE-RELATED, 4, SUSCEPTIBILITY TO

                 CHITOTRIOSIDASE DEFICIENCY

              HAIR MORPHOLOGY 1, HAIR THICKNESS

                  ASTHMA, SUSCEPTIBILITY TO

       MYCOBACTERIUM TUBERCULOSIS, SUSCEPTIBILITY TO

     HUMAN IMMUNODEFICIENCY VIRUS TYPE 1, RESISTANCE TO

                   CALCIUM, SERUM LEVEL OF

         DOWN SYNDROME, SUSCEPTIBILITY TO, INCLUDED

   NEURAL TUBE DEFECTS, FOLATE-SENSITIVE, SUSCEPTIBILITY TO

      SKIN/HAIR/EYE PIGMENTATION 5, BLACK/NONBLACK HAIR

    SKIN/HAIR/EYE PIGMENTATION 5, DARK/FAIR SKIN, INCLUDED

    SKIN/HAIR/EYE PIGMENTATION 5, DARK/LIGHT EYES, INCLUDED

                     HEXB POLYMORPHISM

             ASTHMA, SUSCEPTIBILITY TO, INCLUDED

                   ATOPY, SUSCEPTIBILITY TO

       DERMATITIS, ATOPIC, 6, SUSCEPTIBILITY TO, INCLUDED

                                7

HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT
                            LOCUS

                GMP REDUCTASE POLYMORPHISM

             ASTHMA AND ATOPY, SUSCEPTIBILITY TO

                   ASTHMA SUSCEPTIBILITY 2
                     ASTHMA SUSCEPTIBILITY 2

      CORONARY ARTERY DISEASE, SUSCEPTIBILITY TO, INCLUDED

       CORONARY ARTERY SPASM, SUSCEPTIBILITY TO, INCLUDED

                PON1 ENZYME ACTIVITY, VARIATION IN

      CORONARY ARTERY DISEASE, SUSCEPTIBILITY TO, INCLUDED

 MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 5,
                         INCLUDED

                PON1 ENZYME ACTIVITY, VARIATION IN

                  PARAOXONASE 2 POLYMORPHISM

                  PARAOXONASE 2 POLYMORPHISM

             HYPERTRIGLYCERIDEMIA, SUSCEPTIBILITY TO

   DIABETES MELLITUS, NONINSULIN-DEPENDENT, SUSCEPTIBILITY TO

        AUTOIMMUNE THYROID DISEASE, SUSCEPTIBILITY TO, 3

   CORONARY HEART DISEASE IN FAMILIAL HYPERCHOLESTEROLEMIA,
                     PROTECTION AGAINST

                    PREECLAMPSIA/ECLAMPSIA 4

         ALZHEIMER DISEASE, LATE-ONSET, SUSCEPTIBILITY TO

CONGESTIVE HEART FAILURE AND BETA-BLOCKER RESPONSE, MODIFIER OF

   DIABETES MELLITUS, NONINSULIN-DEPENDENT, SUSCEPTIBILITY TO

         ANOREXIA NERVOSA, SUSCEPTIBILITY TO, 2, INCLUDED

     BIPOLAR AFFECTIVE DISORDER, SUSCEPTIBILITY TO, INCLUDED

          BULIMIA NERVOSA, SUSCEPTIBILITY TO, 2, INCLUDED

              MEMORY IMPAIRMENT, SUSCEPTIBILITY TO

  OBSESSIVE-COMPULSIVE DISORDER, PROTECTION AGAINST, INCLUDED

   PARKINSON DISEASE, AGE AT ONSET, SUSCEPTIBILITY TO, INCLUDED

                 ATOPIC ASTHMA, SUSCEPTIBILITY TO

         SKIN/HAIR/EYE PIGMENTATION 10, BLOND/BROWN HAIR

              ALPHA-2-MACROGLOBULIN POLYMORPHISM

          ALZHEIMER DISEASE, SUSCEPTIBILITY TO, INCLUDED

           DIABETES MELLITUS, TYPE 1, SUSCEPTIBILITY TO

                          HAWKINSINURIA
     BREAST-OVARIAN CANCER, FAMILIAL, SUSCEPTIBILITY TO, 2

          NUCLEOSIDE PHOSPHORYLASE POLYMORPHISM

           CEREBRAL INFARCTION, SUSCEPTIBILITY TO

       ABRUPTIO PLACENTAE, SUSCEPTIBILITY TO, INCLUDED

   NEURAL TUBE DEFECTS, FOLATE-SENSITIVE, SUSCEPTIBILITY TO

            LUMBAR DISC DISEASE, SUSCEPTIBILITY TO

           EXFOLIATION SYNDROME, SUSCEPTIBILITY TO

                FAMILIAL MEDITERRANEAN FEVER

                FAMILIAL MEDITERRANEAN FEVER

      SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO

                   ATOPY, SUSCEPTIBILITY TO

                      EAR WAX, WET/DRY

             BENZENE TOXICITY, SUSCEPTIBILITY TO

BREAST CANCER, POST-CHEMOTHERAPY POOR SURVIVAL IN, INCLUDED

  LEUKEMIA, POST-CHEMOTHERAPY, SUSCEPTIBILITY TO, INCLUDED

                   CODON 72 POLYMORPHISM

        CARDIAC CONDUCTION DEFECT, SUSCEPTIBILITY TO

               COLON CANCER, SUSCEPTIBILITY TO

             HEPATITIS B VIRUS, SUSCEPTIBILITY TO

               SCHIZOPHRENIA, SUSCEPTIBILITY TO

       CATECHOL-O-METHYLTRANSFERASE POLYMORPHISM

                     TCN2 POLYMORPHISM

              DEBRISOQUINE, POOR METABOLISM OF

               ARYLSULFATASE A POLYMORPHISM

               DUCHENNE MUSCULAR DYSTROPHY

               DUCHENNE MUSCULAR DYSTROPHY
Coordinates              Genotype
Gene, amino acid change Trait-associated allele
chr1:9246497             A/A
H6PD, R453Q              A
chr1:25589952            C/G
RHCE, P226A              C
chr1:35023530            G/A
GJB3, A194T              A
chr1:65809029            G/G
LEPR, K109R              G
chr1:65831101            G/G
LEPR, Q223R              G
chr1:152693594           A/C
IL6R, D358A              C
chr1:167963570           G/A
SELE, H468Y              A
chr1:169346704           G/A
FMO3, V257M              A
chr1:194908856           G/A
CFH, I62V                G
chr1:221351222           T/C
TLR5, N592S              C
chr1:224086256           T/C
EPHX1, Y113H             C
chr1:224086256           T/C
EPHX1, Y113H             C
chr1:224086256           T/C
EPHX1, Y113H             C
chr1:224086256           T/C
EPHX1, Y113H             C
chr2:108880033           G/G
EDAR, V370A              G
chr2:230758959           G/G
SP110, L425S             G
chr3:10306457            G/T
GHRL, L72M               T
chr3:10306457            G/T
GHRL, L72M               T
chr4:2876505             T/T
ADD1, G460W              T
chr5:7923973             A/G
MTRR, I22M               G
chr5:7923973             A/G
MTRR, I22M               G
chr5:33999627            C/T
SLC45A2, E272K           T
chr5:33999627            C/T
SLC45A2, E272K           T
chr5:33999627            C/T
SLC45A2, E272K           T
chr5:74020971            A/G
HEXB, K121R              G
chr5:148186633           G/A
ADRB2, R16G              G
chr5:148186633           G/A
ADRB2, R16G       G
chr5:148186666    G/C
ADRB2, Q27E       G
chr5:148186666    G/C
ADRB2, Q27E       G
chr5:148186666    G/C
ADRB2, Q27E       G
chr5:176452849    G/A
FGFR4, G388R      A
chr6:16398740     A/A
GMPR, F256I       A
chr6:36759949     A/A
CDKN1A, S31R      A
chr6:46780902     A/G
PLA2G7, A379V     A
chr6:149763383    G/A
SUMO4, M55V       G
chr6:160033862    A/G
SOD2, A16V        A
chr6:160033862    A/G
SOD2, A16V        A
chr7:34784638     A/T
NPSR1, N107I      T
chr7:94775382     C/C
PON1, Q192R       C
chr7:94775382     C/C
PON1, Q192R       C
chr7:94775382     C/C
PON1, Q192R       C
chr7:141319073    C/C
TAS2R38, I296V    C
chr7:141319814    G/G
TAS2R38, A49P     G
chr8:18302650     G/A
NAT2, G286E       A
chr8:133969434    G/G
TG, S734A         G
chr9:106660688    T/T
ABCA1, R219K      T
chr10:70311866    C/C
STOX1, Y153H      C
chr10:101819504   C/T
CPN1, G178D       T
chr11:17366148    T/C
KCNJ11, E23K      T
chr11:27636492    C/T
BDNF, V66M        T
chr11:27636492    C/T
BDNF, V66M        T
chr11:27636492    C/T
BDNF, V66M        T
chr11:27636492    C/T
BDNF, V66M        T
chr11:27636492    C/T
BDNF, V66M        T
chr11:27636492    C/T
BDNF, V66M        T
chr11:59619680    A/G
MS4A2, E237G      G
chr12:111833253   G/A
OAS1, S162G       G
chr12:120779718   T/C
HPD, A33T         T
chr14:60993992    G/A
PRKCH, V374I      A
chr15:72006599    T/T
LOXL1, R141L      T
chr16:16159100    C/T
ABCC6, R1268Q     T
chr16:27281681    T/C
IL4R, S503P       C
chr16:27281681    T/C
IL4R, S503P       C
chr16:46815699    T/T
ABCC11, G180R     T
chr16:68302646    G/A
NQO1, P187S       A
chr16:68302646    G/A
NQO1, P187S       A
chr16:68302646    G/A
NQO1, P187S       A
chr17:19753133    T/C
AKAP10, I646V     C
chr17:25600202    T/C
BLMH, I443V       C
chr17:39684147    G/A
SLC4A1, P854L     A
chr17:39694471    T/C
SLC4A1, K56E      C
chr19:50014584    A/G
BCAM, T539A       G
chr20:54394948    T/T
AURKA, F31I       T
chr22:17281004    C/T
PRODH, Q521R      C
chr22:17281004    C/T
PRODH, Q521R      C
chr22:18331271    G/A
COMT, V158M       A
chr22:40856638    A/A
CYP2D6, P34S      A
chrX:19285703     C
PDHA1, M282L      C
chrX:113871991    C
HTR2C, C23S       C
                           Associated trait


                 CORTISONE REDUCTASE DEFICIENCY

                        RH E/e POLYMORPHISM

                    DEAFNESS, DIGENIC, GJB2/GJB3

                  LEPTIN RECEPTOR POLYMORPHISM

                  LEPTIN RECEPTOR POLYMORPHISM

          INTERLEUKIN-6 SOLUBLE RECEPTOR, SERUM LEVEL OF

                 IgA NEPHROPATHY, SUSCEPTIBILITY TO

                         TRIMETHYLAMINURIA

      MACULAR DEGENERATION, AGE-RELATED, 4, SUSCEPTIBILITY TO

               LEGIONNAIRE DISEASE, SUSCEPTIBILITY TO

              EMPHYSEMA, SUSCEPTIBILITY TO, INCLUDED

         LYMPHOPROLIFERATIVE DISORDERS, SUSCEPTIBILITY TO

             PREECLAMPSIA, SUSCEPTIBILITY TO, INCLUDED

PULMONARY DISEASE, CHRONIC OBSTRUCTIVE, SUSCEPTIBILITY TO, INCLUDED

                 HAIR MORPHOLOGY 1, HAIR THICKNESS

          MYCOBACTERIUM TUBERCULOSIS, SUSCEPTIBILITY TO

          METABOLIC SYNDROME, SUSCEPTIBILITY TO, INCLUDED

                      OBESITY, AGE AT ONSET OF

     HYPERTENSION, SALT-SENSITIVE ESSENTIAL, SUSCEPTIBILITY TO

            DOWN SYNDROME, SUSCEPTIBILITY TO, INCLUDED

      NEURAL TUBE DEFECTS, FOLATE-SENSITIVE, SUSCEPTIBILITY TO

         SKIN/HAIR/EYE PIGMENTATION 5, BLACK/NONBLACK HAIR

       SKIN/HAIR/EYE PIGMENTATION 5, DARK/FAIR SKIN, INCLUDED

       SKIN/HAIR/EYE PIGMENTATION 5, DARK/LIGHT EYES, INCLUDED

                        HEXB POLYMORPHISM

               ASTHMA, NOCTURNAL, SUSCEPTIBILITY TO

          METABOLIC SYNDROME, SUSCEPTIBILITY TO, INCLUDED
       METABOLIC SYNDROME, SUSCEPTIBILITY TO, INCLUDED

       ASTHMA, CHILDHOOD, SUSCEPTIBILITY TO, INCLUDED

       METABOLIC SYNDROME, SUSCEPTIBILITY TO, INCLUDED

                  OBESITY, SUSCEPTIBILITY TO

        CANCER PROGRESSION AND TUMOR CELL MOTILITY

                GMP REDUCTASE POLYMORPHISM

         CIP1/WAF1 TUMOR-ASSOCIATED POLYMORPHISM 1

             ASTHMA AND ATOPY, SUSCEPTIBILITY TO

           DIABETES MELLITUS, INSULIN-DEPENDENT, 5

MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 6,
                        INCLUDED

            SUPEROXIDE DISMUTASE 2 POLYMORPHISM

                   ASTHMA SUSCEPTIBILITY 2

    CORONARY ARTERY DISEASE, SUSCEPTIBILITY TO, INCLUDED

     CORONARY ARTERY SPASM, SUSCEPTIBILITY TO, INCLUDED

              PON1 ENZYME ACTIVITY, VARIATION IN

                PHENYLTHIOCARBAMIDE TASTING

                PHENYLTHIOCARBAMIDE TASTING

                      ACETYLATION, SLOW

       AUTOIMMUNE THYROID DISEASE, SUSCEPTIBILITY TO, 3

 CORONARY HEART DISEASE IN FAMILIAL HYPERCHOLESTEROLEMIA,
                   PROTECTION AGAINST

                  PREECLAMPSIA/ECLAMPSIA 4

               CARBOXYPEPTIDASE N DEFICIENCY

 DIABETES MELLITUS, NONINSULIN-DEPENDENT, SUSCEPTIBILITY TO

       ANOREXIA NERVOSA, SUSCEPTIBILITY TO, 2, INCLUDED

   BIPOLAR AFFECTIVE DISORDER, SUSCEPTIBILITY TO, INCLUDED

        BULIMIA NERVOSA, SUSCEPTIBILITY TO, 2, INCLUDED

            MEMORY IMPAIRMENT, SUSCEPTIBILITY TO

OBSESSIVE-COMPULSIVE DISORDER, PROTECTION AGAINST, INCLUDED

 PARKINSON DISEASE, AGE AT ONSET, SUSCEPTIBILITY TO, INCLUDED
              ATOPIC ASTHMA, SUSCEPTIBILITY TO

         DIABETES MELLITUS, TYPE 1, SUSCEPTIBILITY TO

                       HAWKINSINURIA

           CEREBRAL INFARCTION, SUSCEPTIBILITY TO

          EXFOLIATION SYNDROME, SUSCEPTIBILITY TO

                PSEUDOXANTHOMA ELASTICUM

                 ASTHMA, SUSCEPTIBILITY TO

                    ATOPY, RESISTANCE TO

                      EAR WAX, WET/DRY

             BENZENE TOXICITY, SUSCEPTIBILITY TO

BREAST CANCER, POST-CHEMOTHERAPY POOR SURVIVAL IN, INCLUDED

  LEUKEMIA, POST-CHEMOTHERAPY, SUSCEPTIBILITY TO, INCLUDED

        CARDIAC CONDUCTION DEFECT, SUSCEPTIBILITY TO

            BLEOMYCIN HYDROLASE POLYMORPHISM

                DIEGO BLOOD GROUP ANTIGEN

                       BAND 3 MEMPHIS

       AUBERGER BLOOD GROUP POLYMORPHISM Au(a)/Au(b)

              COLON CANCER, SUSCEPTIBILITY TO

                  HYPERPROLINEMIA, TYPE I

        SCHIZOPHRENIA, SUSCEPTIBILITY TO, 4, INCLUDED

       CATECHOL-O-METHYLTRANSFERASE POLYMORPHISM

             DEBRISOQUINE, POOR METABOLISM OF

       PYRUVATE DEHYDROGENASE E1-ALPHA DEFICIENCY

         SEROTONIN 5-HT-2C RECEPTOR POLYMORPHISM
Coordinates               Genotype
Gene, amino acid change   Trait-associated allele
chr1:9246497              A/A
H6PD, R453Q               A
chr1:25589952             C/G
RHCE, P226A               C
chr1:65809029             G/G
LEPR, K109R               G
chr1:65831101             A/G
LEPR, Q223R               G
chr1:152693594            C/C
IL6R, D358A               C
chr1:167963570            G/A
SELE, H468Y               A
chr1:180821180            T/T
RNASEL, R462Q             T
chr1:194908856            G/A
CFH, I62V                 G
chr1:201460809            T/T
CHIT1, G102S              T
chr1:221351222            T/C
TLR5, N592S               C
chr2:49043425             C/T
FSHR, N680S               C
chr2:49043425             C/T
FSHR, N680S               C
chr2:49044545             C/T
FSHR, T307A               C
chr2:108880033            A/G
EDAR, V370A               G
chr2:230758959            G/G
SP110, L425S              G
chr2:233848107            G/G
ATG16L1, T300A            G
chr2:234334358            C/A
UGT1A1, P229Q             A
chr2:234334358            C/A
UGT1A1, P229Q             A
chr3:115373505            C/T
DRD3, S9G                 C
chr3:115373505            C/T
DRD3, S9G                 C
chr4:2876505              T/T
ADD1, G460W               T
chr5:33999627             C/T
SLC45A2, E272K            T
chr5:33999627             C/T
SLC45A2, E272K            T
chr5:33999627             C/T
SLC45A2, E272K            T
chr5:35896825             T/C
IL7R, T66I                T
chr5:35896825             T/C
IL7R, T66I                T
chr5:35906947             G/A
IL7R, I138V      G
chr5:35906947    G/A
IL7R, I138V      G
chr6:12404241    T/T
EDN1, K198N      T
chr6:12404241    T/T
EDN1, K198N      T
chr6:16398740    A/A
GMPR, F256I      A
chr6:32022159    G/A
CFB, R32Q        A
chr6:46785057    C/A
PLA2G7, V279F    A
chr6:46787262    A/G
PLA2G7, I198T    G
chr7:34784638    A/T
NPSR1, N107I     T
chr7:94775382    T/C
PON1, Q192R      C
chr7:94775382    T/C
PON1, Q192R      C
chr7:94775382    T/C
PON1, Q192R      C
chr7:94784020    A/T
PON1, L55M       T
chr7:94784020    A/T
PON1, L55M       T
chr7:94784020    A/T
PON1, L55M       T
chr7:94872711    G/C
PON2, C311S      G
chr7:94878952    G/C
PON2, A148G      C
chr7:141319073   C/C
TAS2R38, I296V   C
chr7:141319814   G/G
TAS2R38, A49P    G
chr8:18302650    G/A
NAT2, G286E      A
chr8:118253964   C/T
SLC30A8, R325W   T
chr10:70311866   C/C
STOX1, Y153H     C
chr11:17366148   T/C
KCNJ11, E23K     T
chr11:27636492   C/T
BDNF, V66M       T
chr11:27636492   C/T
BDNF, V66M       T
chr11:27636492   C/T
BDNF, V66M       T
chr11:27636492   C/T
BDNF, V66M       T
chr11:27636492   C/T
BDNF, V66M       T
chr11:27636492   C/T
BDNF, V66M       T
chr12:14884706     C/T
ART4, N265D        C
chr13:31804729     A/C
BRCA2, N372H       C
chr13:107661592    G/A
LIG4, T9I          A
chr13:107661610    G/A
LIG4, A3V          A
chr14:20010446     G/A
NP, S51G           G
chr15:25902148     C/T
OCA2, A481T        T
chr15:72006599     T/T
LOXL1, R141L       T
chr16:3647748      G/A
DNASE1, Q244R      G
chr16:27281681     T/C
IL4R, S503P        C
chr16:27281681     T/C
IL4R, S503P        C
chr16:27281901     A/G
IL4R, Q576R        G
chr16:46815699     T/T
ABCC11, G180R      T
chr16:68302646     G/A
NQO1, P187S        A
chr16:68302646     G/A
NQO1, P187S        A
chr16:68302646     G/A
NQO1, P187S        A
chr18:9107867      T/C
NDUFV2, A29V       T
chr20:3141842      C/A
ITPA, P32T         A
chr20:54394948     T/T
AURKA, F31I        T
chr22:18331271     G/A
COMT, V158M        A
chr22:29341610     G/C
TCN2, P259R        G
chrX:19285703      A/C
PDHA1, M282L       C
chrX:119644657     A/T
C1GALT1C1, D131E   T
                            Associated trait


                  CORTISONE REDUCTASE DEFICIENCY

                        RH E/e POLYMORPHISM

                   LEPTIN RECEPTOR POLYMORPHISM

                   LEPTIN RECEPTOR POLYMORPHISM

           INTERLEUKIN-6 SOLUBLE RECEPTOR, SERUM LEVEL OF

                 IgA NEPHROPATHY, SUSCEPTIBILITY TO

                 PROSTATE CANCER, SUSCEPTIBILITY TO

       MACULAR DEGENERATION, AGE-RELATED, 4, SUSCEPTIBILITY TO

                     CHITOTRIOSIDASE DEFICIENCY

               LEGIONNAIRE DISEASE, SUSCEPTIBILITY TO

OVARIAN HYPERSTIMULATION SYNDROME, MODIFIER OF SEVERITY OF, INCLUDED

                OVARIAN RESPONSE TO FSH STIMULATION

                OVARIAN RESPONSE TO FSH STIMULATION

                 HAIR MORPHOLOGY 1, HAIR THICKNESS

           MYCOBACTERIUM TUBERCULOSIS, SUSCEPTIBILITY TO

          INFLAMMATORY BOWEL DISEASE 10, SUSCEPTIBILITY TO

             CRIGLER-NAJJAR SYNDROME, TYPE II, INCLUDED

                          GILBERT SYNDROME

            ESSENTIAL TREMOR, SUSCEPTIBILITY TO, INCLUDED

                  SCHIZOPHRENIA, SUSCEPTIBILITY TO

      HYPERTENSION, SALT-SENSITIVE ESSENTIAL, SUSCEPTIBILITY TO

          SKIN/HAIR/EYE PIGMENTATION 5, BLACK/NONBLACK HAIR

        SKIN/HAIR/EYE PIGMENTATION 5, DARK/FAIR SKIN, INCLUDED

       SKIN/HAIR/EYE PIGMENTATION 5, DARK/LIGHT EYES, INCLUDED

                   B CELL-POSITIVE, NK CELL-POSITIVE

  SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-
                           NEGATIVE,

                   B CELL-POSITIVE, NK CELL-POSITIVE
                  B CELL-POSITIVE, NK CELL-POSITIVE

 SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-
                          NEGATIVE,

                                  7

HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS

                   GMP REDUCTASE POLYMORPHISM

       MACULAR DEGENERATION, AGE-RELATED, REDUCED RISK OF

      PLATELET-ACTIVATING FACTOR ACETYLHYDROLASE DEFICIENCY

                ASTHMA AND ATOPY, SUSCEPTIBILITY TO

                      ASTHMA SUSCEPTIBILITY 2

       CORONARY ARTERY DISEASE, SUSCEPTIBILITY TO, INCLUDED

        CORONARY ARTERY SPASM, SUSCEPTIBILITY TO, INCLUDED

                 PON1 ENZYME ACTIVITY, VARIATION IN

       CORONARY ARTERY DISEASE, SUSCEPTIBILITY TO, INCLUDED

   MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 5,
                           INCLUDED

                 PON1 ENZYME ACTIVITY, VARIATION IN

                   PARAOXONASE 2 POLYMORPHISM

                   PARAOXONASE 2 POLYMORPHISM

                   PHENYLTHIOCARBAMIDE TASTING

                   PHENYLTHIOCARBAMIDE TASTING

                         ACETYLATION, SLOW

     DIABETES MELLITUS, NONINSULIN-DEPENDENT, SUSCEPTIBILITY TO

                     PREECLAMPSIA/ECLAMPSIA 4

     DIABETES MELLITUS, NONINSULIN-DEPENDENT, SUSCEPTIBILITY TO

          ANOREXIA NERVOSA, SUSCEPTIBILITY TO, 2, INCLUDED

      BIPOLAR AFFECTIVE DISORDER, SUSCEPTIBILITY TO, INCLUDED

           BULIMIA NERVOSA, SUSCEPTIBILITY TO, 2, INCLUDED

               MEMORY IMPAIRMENT, SUSCEPTIBILITY TO

   OBSESSIVE-COMPULSIVE DISORDER, PROTECTION AGAINST, INCLUDED

    PARKINSON DISEASE, AGE AT ONSET, SUSCEPTIBILITY TO, INCLUDED
                   DOMBROCK BLOOD GROUP

     BREAST-OVARIAN CANCER, FAMILIAL, SUSCEPTIBILITY TO, 2

              MULTIPLE MYELOMA, RESISTANCE TO

              MULTIPLE MYELOMA, RESISTANCE TO

          NUCLEOSIDE PHOSPHORYLASE POLYMORPHISM

              ALBINISM, OCULOCUTANEOUS, TYPE II

           EXFOLIATION SYNDROME, SUSCEPTIBILITY TO

      SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO

                  ASTHMA, SUSCEPTIBILITY TO

                    ATOPY, RESISTANCE TO

                   ATOPY, SUSCEPTIBILITY TO

                      EAR WAX, WET/DRY

             BENZENE TOXICITY, SUSCEPTIBILITY TO

BREAST CANCER, POST-CHEMOTHERAPY POOR SURVIVAL IN, INCLUDED

  LEUKEMIA, POST-CHEMOTHERAPY, SUSCEPTIBILITY TO, INCLUDED

            PARKINSON DISEASE, SUSCEPTIBILITY TO

             INOSINE TRIPHOSPHATASE DEFICIENCY

               COLON CANCER, SUSCEPTIBILITY TO

       CATECHOL-O-METHYLTRANSFERASE POLYMORPHISM

                     TCN2 POLYMORPHISM

        PYRUVATE DEHYDROGENASE E1-ALPHA DEFICIENCY

                         Tn SYNDROME
Coordinates               Genotype
Gene, amino acid change   Trait-associated allele
chr1:9246497              A/A
H6PD, R453Q               A
chr1:46643348             C/A
FAAH, P129T               A
chr1:65809029             G/G
LEPR, K109R               G
chr1:65831101             G/G
LEPR, Q223R               G
chr1:167963570            G/A
SELE, H468Y               A
chr1:180821180            C/T
RNASEL, R462Q             T
chr1:194908856            G/A
CFH, I62V                 G
chr1:224086256            T/C
EPHX1, Y113H              C
chr1:224086256            T/C
EPHX1, Y113H              C
chr1:224086256            T/C
EPHX1, Y113H              C
chr1:224086256            T/C
EPHX1, Y113H              C
chr2:218967976            G/A
SLC11A1, D543N            A
chr2:230758959            G/G
SP110, L425S              G
chr2:233848107            A/G
ATG16L1, T300A            G
chr3:10306457             G/T
GHRL, L72M                T
chr3:10306457             G/T
GHRL, L72M                T
chr4:2876505              G/T
ADD1, G460W               T
chr4:102970099            G/A
BANK1, R61H               A
chr5:7923973              A/G
MTRR, I22M                G
chr5:7923973              A/G
MTRR, I22M                G
chr5:147461148            A/G
SPINK5, E420K             A
chr5:147461148            A/G
SPINK5, E420K             A
chr5:147461148            A/G
SPINK5, E420K             A
chr5:148186633            G/A
ADRB2, R16G               G
chr5:148186633            G/A
ADRB2, R16G               G
chr6:16398740             A/A
GMPR, F256I               A
chr7:34784638             A/T
NPSR1, N107I              T
chr7:44071364     C/T
PGAM2, G97D       T
chr7:94775382     C/C
PON1, Q192R       C
chr7:94775382     C/C
PON1, Q192R       C
chr7:94775382     C/C
PON1, Q192R       C
chr7:141319073    C/C
TAS2R38, I296V    C
chr7:141319814    G/G
TAS2R38, A49P     G
chr8:18302650     G/A
NAT2, G286E       A
chr8:37942955     A/G
ADRB3, W64R       G
chr8:55701948     A/T
RP1, N985Y        T
chr8:133969434    G/G
TG, S734A         G
chr9:106660688    C/T
ABCA1, R219K      T
chr10:54201241    C/T
MBL2, G54D        T
chr10:54201241    C/T
MBL2, G54D        T
chr10:70311866    T/C
STOX1, Y153H      C
chr10:70315382    A/C
STOX1, E608D      C
chr11:125668053   C/T
TIRAP, S180L      T
chr11:125668053   C/T
TIRAP, S180L      T
chr11:125668053   C/T
TIRAP, S180L      T
chr11:125668053   C/T
TIRAP, S180L      T
chr13:31804729    C/C
BRCA2, N372H      C
chr13:107661592   G/A
LIG4, T9I         A
chr13:107661610   G/A
LIG4, A3V         A
chr15:72006635    G/A
LOXL1, G153D      A
chr16:16159100    C/T
ABCC6, R1268Q     T
chr16:46815699    T/T
ABCC11, G180R     T
chr16:67424748    G/A
CDH1, V832M       A
chr17:5426091     A/T
NLRP1, L155H      T
chr17:7520197     C/C
TP53, P72R        C
chr17:19753133    T/C
AKAP10, I646V      C
chr18:9107867      T/C
NDUFV2, A29V       T
chr20:3141842      C/A
ITPA, P32T         A
chr20:47003521     G/A
ARFGEF2, E209K     A
chr20:54394948     T/T
AURKA, F31I        T
chr21:33536120     T/C
IFNAR2, S8F        T
chr21:33562658     A/G
IL10RB, E47K       A
chr22:17285899     G/A
PRODH, R453C       A
chr22:17285899     G/A
PRODH, R453C       A
chrX:19285703      A/C
PDHA1, M282L       C
chrX:119644657     A/T
C1GALT1C1, D131E   T
                            Associated trait

                 CORTISONE REDUCTASE DEFICIENCY

                 DRUG ADDICTION, SUSCEPTIBILITY TO

                  LEPTIN RECEPTOR POLYMORPHISM

                  LEPTIN RECEPTOR POLYMORPHISM

                 IgA NEPHROPATHY, SUSCEPTIBILITY TO

                PROSTATE CANCER, SUSCEPTIBILITY TO

      MACULAR DEGENERATION, AGE-RELATED, 4, SUSCEPTIBILITY TO

              EMPHYSEMA, SUSCEPTIBILITY TO, INCLUDED

         LYMPHOPROLIFERATIVE DISORDERS, SUSCEPTIBILITY TO

             PREECLAMPSIA, SUSCEPTIBILITY TO, INCLUDED

PULMONARY DISEASE, CHRONIC OBSTRUCTIVE, SUSCEPTIBILITY TO, INCLUDED

                  BURULI ULCER, SUSCEPTIBILITY TO

          MYCOBACTERIUM TUBERCULOSIS, SUSCEPTIBILITY TO

         INFLAMMATORY BOWEL DISEASE 10, SUSCEPTIBILITY TO

         METABOLIC SYNDROME, SUSCEPTIBILITY TO, INCLUDED

                      OBESITY, AGE AT ONSET OF

     HYPERTENSION, SALT-SENSITIVE ESSENTIAL, SUSCEPTIBILITY TO

          SYSTEMIC LUPUS ERYTHMATOSUS, ASSOCIATION WITH

            DOWN SYNDROME, SUSCEPTIBILITY TO, INCLUDED

      NEURAL TUBE DEFECTS, FOLATE-SENSITIVE, SUSCEPTIBILITY TO

                ASTHMA, SUSCEPTIBILITY TO, INCLUDED

                      ATOPY, SUSCEPTIBILITY TO

          DERMATITIS, ATOPIC, 6, SUSCEPTIBILITY TO, INCLUDED

               ASTHMA, NOCTURNAL, SUSCEPTIBILITY TO

         METABOLIC SYNDROME, SUSCEPTIBILITY TO, INCLUDED

                   GMP REDUCTASE POLYMORPHISM

                      ASTHMA SUSCEPTIBILITY 2
                    GLYCOGEN STORAGE DISEASE X

        CORONARY ARTERY DISEASE, SUSCEPTIBILITY TO, INCLUDED

         CORONARY ARTERY SPASM, SUSCEPTIBILITY TO, INCLUDED

                  PON1 ENZYME ACTIVITY, VARIATION IN

                    PHENYLTHIOCARBAMIDE TASTING

                    PHENYLTHIOCARBAMIDE TASTING

                          ACETYLATION, SLOW

                      OBESITY, SUSCEPTIBILITY TO

               HYPERTRIGLYCERIDEMIA, SUSCEPTIBILITY TO

           AUTOIMMUNE THYROID DISEASE, SUSCEPTIBILITY TO, 3

CORONARY HEART DISEASE IN FAMILIAL HYPERCHOLESTEROLEMIA, PROTECTION
                              AGAINST

      GESTATIONAL DIABETES MELLITUS, SUSCEPTIBILITY TO, INCLUDED

                 MANNOSE-BINDING PROTEIN DEFICIENCY

                      PREECLAMPSIA/ECLAMPSIA 4

                      PREECLAMPSIA/ECLAMPSIA 4

              BACTEREMIA, PROTECTION AGAINST, INCLUDED

         INVASIVE PNEUMOCOCCAL DISEASE, PROTECTION AGAINST

                  MALARIA, RESISTANCE TO, INCLUDED

     MYCOBACTERIUM TUBERCULOSIS, PROTECTION AGAINST, INCLUDED

         BREAST-OVARIAN CANCER, FAMILIAL, SUSCEPTIBILITY TO, 2

                  MULTIPLE MYELOMA, RESISTANCE TO

                  MULTIPLE MYELOMA, RESISTANCE TO

               EXFOLIATION SYNDROME, SUSCEPTIBILITY TO

                     PSEUDOXANTHOMA ELASTICUM

                          EAR WAX, WET/DRY

                   GASTRIC CANCER, FAMILIAL DIFFUSE

   VITILIGO-ASSOCIATED MULTIPLE AUTOIMMUNE DISEASE SUSCEPTIBILITY 1

                       CODON 72 POLYMORPHISM

            CARDIAC CONDUCTION DEFECT, SUSCEPTIBILITY TO
           CARDIAC CONDUCTION DEFECT, SUSCEPTIBILITY TO

                PARKINSON DISEASE, SUSCEPTIBILITY TO

                INOSINE TRIPHOSPHATASE DEFICIENCY

PERIVENTRICULAR HETEROTOPIA WITH MICROCEPHALY, AUTOSOMAL RECESSIVE

                  COLON CANCER, SUSCEPTIBILITY TO

                 HEPATITIS B VIRUS, SUSCEPTIBILITY TO

                 HEPATITIS B VIRUS, SUSCEPTIBILITY TO

                      HYPERPROLINEMIA, TYPE I

            SCHIZOPHRENIA, SUSCEPTIBILITY TO, 4, INCLUDED

           PYRUVATE DEHYDROGENASE E1-ALPHA DEFICIENCY

                            Tn SYNDROME
Coordinates               Genotype
Gene, amino acid change   Trait-associated allele
chr1:9246497              G/A
H6PD, R453Q               A
chr1:65809029             G/G
LEPR, K109R               G
chr1:65831101             G/G
LEPR, Q223R               G
chr1:98121473             G/A
DPYD, C29R                G
chr1:152693594            A/C
IL6R, D358A               C
chr1:159910422            T/C
FCGR2B, I232T             C
chr1:159910422            T/C
FCGR2B, I232T             C
chr1:169346704            G/A
FMO3, V257M               A
chr1:194908856            G/A
CFH, I62V                 G
chr2:108880033            G/G
EDAR, V370A               G
chr2:218967976            G/A
SLC11A1, D543N            A
chr2:230758959            G/G
SP110, L425S              G
chr2:233848107            A/G
ATG16L1, T300A            G
chr2:234333883            G/A
UGT1A1, G71R              A
chr2:234333883            G/A
UGT1A1, G71R              A
chr4:2876505              G/T
ADD1, G460W               T
chr4:100458342            T/C
ADH1B, R48H               T
chr4:100458342            T/C
ADH1B, R48H               T
chr5:33999627             C/T
SLC45A2, E272K            T
chr5:33999627             C/T
SLC45A2, E272K            T
chr5:33999627             C/T
SLC45A2, E272K            T
chr5:147461148            A/G
SPINK5, E420K             A
chr5:147461148            A/G
SPINK5, E420K             A
chr5:147461148            A/G
SPINK5, E420K             A
chr5:148186633            G/A
ADRB2, R16G               G
chr5:148186633            G/A
ADRB2, R16G               G
chr6:16398740             A/A
GMPR, F256I               A
chr6:46785057     C/A
PLA2G7, V279F     A
chr6:46787262     A/G
PLA2G7, I198T     G
chr6:149763383    G/A
SUMO4, M55V       G
chr7:94775382     C/C
PON1, Q192R       C
chr7:94775382     C/C
PON1, Q192R       C
chr7:94775382     C/C
PON1, Q192R       C
chr7:141319073    T/C
TAS2R38, I296V    C
chr7:141319174    G/A
TAS2R38, V262A    G
chr7:141319814    C/G
TAS2R38, A49P     G
chr8:118253964    C/T
SLC30A8, R325W    T
chr8:133969434    G/G
TG, S734A         G
chr9:106660688    C/T
ABCA1, R219K      T
chr10:54201241    C/T
MBL2, G54D        T
chr10:54201241    C/T
MBL2, G54D        T
chr10:64085190    A/G
ZNF365, A62T      A
chr10:70311866    C/C
STOX1, Y153H      C
chr11:17366148    T/C
KCNJ11, E23K      T
chr11:27636492    C/T
BDNF, V66M        T
chr11:27636492    C/T
BDNF, V66M        T
chr11:27636492    C/T
BDNF, V66M        T
chr11:27636492    C/T
BDNF, V66M        T
chr11:27636492    C/T
BDNF, V66M        T
chr11:27636492    C/T
BDNF, V66M        T
chr12:9123535     T/C
A2M, V1000I       T
chr12:9123535     T/C
A2M, V1000I       T
chr12:119901033   C/C
HNF1A, I27L       C
chr12:119901033   C/C
HNF1A, I27L       C
chr12:120779718   T/C
HPD, A33T         T
chr13:31804729    A/C
BRCA2, N372H     C
chr14:60993992   G/A
PRKCH, V374I     A
chr15:63281265   A/G
CILP, I395T      G
chr15:72006599   G/T
LOXL1, R141L     T
chr16:27281681   T/C
IL4R, S503P      C
chr16:27281681   T/C
IL4R, S503P      C
chr16:27281901   A/G
IL4R, Q576R      G
chr16:46815699   T/T
ABCC11, G180R    T
chr16:68302646   G/A
NQO1, P187S      A
chr16:68302646   G/A
NQO1, P187S      A
chr16:68302646   G/A
NQO1, P187S      A
chr17:7520197    C/C
TP53, P72R       C
chr17:19753133   C/C
AKAP10, I646V    C
chr17:35133114   A/G
ERBB2, V655I     A
chr17:39694471   T/C
SLC4A1, K56E     C
chr20:3141842    C/A
ITPA, P32T       A
chr20:54394948   A/T
AURKA, F31I      T
chr22:17281004   C/T
PRODH, Q521R     C
chr22:17281004   C/T
PRODH, Q521R     C
chr22:18330263   T/T
COMT, A72S       T
chrX:19285703    C
PDHA1, M282L     C
                              Associated trait

                    CORTISONE REDUCTASE DEFICIENCY

                     LEPTIN RECEPTOR POLYMORPHISM

                     LEPTIN RECEPTOR POLYMORPHISM

             DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY

            INTERLEUKIN-6 SOLUBLE RECEPTOR, SERUM LEVEL OF

    MALARIA, RESISTANCE TO, INCLUDED SYSTEMIC LUPUS ERYTHEMATOSIS,
                      SUSCEPTIBILITY TO, INCLUDED

           SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO

                           TRIMETHYLAMINURIA

        MACULAR DEGENERATION, AGE-RELATED, 4, SUSCEPTIBILITY TO

                   HAIR MORPHOLOGY 1, HAIR THICKNESS

                     BURULI ULCER, SUSCEPTIBILITY TO

            MYCOBACTERIUM TUBERCULOSIS, SUSCEPTIBILITY TO

           INFLAMMATORY BOWEL DISEASE 10, SUSCEPTIBILITY TO

                           GILBERT SYNDROME

       HYPERBILIRUBINEMIA, TRANSIENT FAMILIAL NEONATAL, INCLUDED

        HYPERTENSION, SALT-SENSITIVE ESSENTIAL, SUSCEPTIBILITY TO

AERODIGESTIVE TRACT CANCER, SQUAMOUS CELL, ALCOHOL-RELATED, PROTECTION
                          AGAINST; INCLUDED

               ALCOHOL DEPENDENCE, PROTECTION AGAINST

           SKIN/HAIR/EYE PIGMENTATION 5, BLACK/NONBLACK HAIR

          SKIN/HAIR/EYE PIGMENTATION 5, DARK/FAIR SKIN, INCLUDED

         SKIN/HAIR/EYE PIGMENTATION 5, DARK/LIGHT EYES, INCLUDED

                   ASTHMA, SUSCEPTIBILITY TO, INCLUDED

                        ATOPY, SUSCEPTIBILITY TO

            DERMATITIS, ATOPIC, 6, SUSCEPTIBILITY TO, INCLUDED

                  ASTHMA, NOCTURNAL, SUSCEPTIBILITY TO

            METABOLIC SYNDROME, SUSCEPTIBILITY TO, INCLUDED

                     GMP REDUCTASE POLYMORPHISM
      PLATELET-ACTIVATING FACTOR ACETYLHYDROLASE DEFICIENCY

                 ASTHMA AND ATOPY, SUSCEPTIBILITY TO

               DIABETES MELLITUS, INSULIN-DEPENDENT, 5

        CORONARY ARTERY DISEASE, SUSCEPTIBILITY TO, INCLUDED

         CORONARY ARTERY SPASM, SUSCEPTIBILITY TO, INCLUDED

                  PON1 ENZYME ACTIVITY, VARIATION IN

                    PHENYLTHIOCARBAMIDE TASTING

                    PHENYLTHIOCARBAMIDE TASTING

                    PHENYLTHIOCARBAMIDE TASTING

     DIABETES MELLITUS, NONINSULIN-DEPENDENT, SUSCEPTIBILITY TO

           AUTOIMMUNE THYROID DISEASE, SUSCEPTIBILITY TO, 3

CORONARY HEART DISEASE IN FAMILIAL HYPERCHOLESTEROLEMIA, PROTECTION
                              AGAINST

      GESTATIONAL DIABETES MELLITUS, SUSCEPTIBILITY TO, INCLUDED

                 MANNOSE-BINDING PROTEIN DEFICIENCY

             URIC ACID NEPHROLITHIASIS, SUSCEPTIBILITY TO

                      PREECLAMPSIA/ECLAMPSIA 4

     DIABETES MELLITUS, NONINSULIN-DEPENDENT, SUSCEPTIBILITY TO

           ANOREXIA NERVOSA, SUSCEPTIBILITY TO, 2, INCLUDED

       BIPOLAR AFFECTIVE DISORDER, SUSCEPTIBILITY TO, INCLUDED

            BULIMIA NERVOSA, SUSCEPTIBILITY TO, 2, INCLUDED

                MEMORY IMPAIRMENT, SUSCEPTIBILITY TO

    OBSESSIVE-COMPULSIVE DISORDER, PROTECTION AGAINST, INCLUDED

     PARKINSON DISEASE, AGE AT ONSET, SUSCEPTIBILITY TO, INCLUDED

                ALPHA-2-MACROGLOBULIN POLYMORPHISM

            ALZHEIMER DISEASE, SUSCEPTIBILITY TO, INCLUDED

                INSULIN RESISTANCE, SUSCEPTIBILITY TO

         SERUM HDL CHOLESTEROL LEVEL, MODIFIER OF, INCLUDED

                            HAWKINSINURIA

         BREAST-OVARIAN CANCER, FAMILIAL, SUSCEPTIBILITY TO, 2
     BREAST-OVARIAN CANCER, FAMILIAL, SUSCEPTIBILITY TO, 2

           CEREBRAL INFARCTION, SUSCEPTIBILITY TO

            LUMBAR DISC DISEASE, SUSCEPTIBILITY TO

           EXFOLIATION SYNDROME, SUSCEPTIBILITY TO

                  ASTHMA, SUSCEPTIBILITY TO

                    ATOPY, RESISTANCE TO

                   ATOPY, SUSCEPTIBILITY TO

                      EAR WAX, WET/DRY

             BENZENE TOXICITY, SUSCEPTIBILITY TO

BREAST CANCER, POST-CHEMOTHERAPY POOR SURVIVAL IN, INCLUDED

  LEUKEMIA, POST-CHEMOTHERAPY, SUSCEPTIBILITY TO, INCLUDED

                   CODON 72 POLYMORPHISM

        CARDIAC CONDUCTION DEFECT, SUSCEPTIBILITY TO

                     ERBB2 POLYMORPHISM

                       BAND 3 MEMPHIS

             INOSINE TRIPHOSPHATASE DEFICIENCY

               COLON CANCER, SUSCEPTIBILITY TO

                   HYPERPROLINEMIA, TYPE I

        SCHIZOPHRENIA, SUSCEPTIBILITY TO, 4, INCLUDED

               SCHIZOPHRENIA, SUSCEPTIBILITY TO

        PYRUVATE DEHYDROGENASE E1-ALPHA DEFICIENCY

				
DOCUMENT INFO
Shared By:
Categories:
Tags:
Stats:
views:11
posted:7/28/2011
language:English
pages:106